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METHODS AND COMPOSITIONS 
COMPRISING AC-TERMINAL BAX PEPTIDE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a National Phase Application of Inter-
national Application No. PCT/US2012/052354 filedAug. 24, 
2012, which claims priority to U.S. Provisional Application 
No. 61/527,524 filed Aug. 25, 2011 and to U.S. Provisional 
Application No. 61/645,891 filed May 11, 2012, each of 
which is incorporated herein fully by reference. 
This invention was made with govermnent support under 
GM083324 awarded by the National Institutes of Heath/ 
NIGMS. The United States government has certain rights in 
the invention. 
REFERENCE TO SEQUENCE LISTING 
The Sequence Listing submitted Nov. 21, 2014 as a text file 
named "21650_0024U2_revised_sequence_listing.txt," cre-
ated on Nov. 21, 2014 and having a size of 17,889 bytes, is 
hereby incorporated by reference pursuant to 37 C.F.R. § 1.52 
( e )(5). 
BACKGROUND 
2 
prise administering to at least a cell an effective amount of a 
C-terminal Bax peptide (CT20p peptide) or a composition 
comprising an effective amount of a CT20p peptide. 
Disclosed herein is a method of killing cancer cells in a 
5 subject comprising administering to at least one cell of a 
subject an effective amount ofCT20p peptide or a composi-
tion comprising an effective amount of CT20p peptide. As 
used herein, CT20, CT20p peptide or CT20p peptide refers to 
a peptide comprising the last 20 amino acids of the Bax 
1° C-terminus. 
Disclosed herein is a method of killing microbial cells, 
including but not limited to bacteria and fungi, whether on a 
surface, present in a colony or in a subject, comprising admin-
15 istering to at least one cell of a subject an effective amount of 
a CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide. 
Disclosed herein is a method of permeabilizing mem-
branes of cells. Such membranes may be outer membranes, 
20 cell membranes or interior cellular membranes. The cells may 
be individual cells or cells in a subject. The method comprises 
(i) administering an effective amount of a CT20p peptide, and 
(ii) forming at least one pore in a membrane of at least one 
cell, wherein the peptide or a composition comprising an 
25 effective amount of a CT20p peptide destabilizes at least one 
membrane, facilitates ion exchange, and/or causes a seques-
tered molecule to be released. 
The ability to kill cells provides a powerful therapeutic 
approach to treatment of disease or infection. Bacteria and 
fungi are becoming resistant to many of the currently avail- 30 
able antimicrobial or antimycotic therapeutic compounds. 
Cancer cells frequently acquire mutations that enhance resis-
tance to standard treatments. Principal among these mecha-
nisms of drug resistance is abnormal expression of members 
Disclosed herein is a method of killing cancer cells in a 
subject comprising (i) administering to a subject an effective 
amount of a CT20p peptide, (ii) permeabilizing at least one 
membrane in a cell of the subject, and (iii) inducing cell death. 
Disclosed herein is a method of killing bacterial or fungal 
cells in a subject comprising (i) administering to a subject an 
effective amount of a CT20p peptide, (ii) permeabilizing at 
least one membrane in a cell of the subject, and (iii) inducing 
cell death. 
of the B cell lymphoma-2 (Bcl-2) family (Oltersdorf et al., 35 
2005). The Bcl-2 family consists of more than twenty anti-
and pro-apoptotic members that modulate the balance 
between life and death. Tumors expressing high levels of 
anti-apoptotic proteins, such as Bcl-2, Mcl-1 or Bel-xi, can be 
resistant to the effects of chemotherapeutics (Oltersdorf et al., 40 
2005). This is accomplished, in part, by inhibition of the 
pro-apoptotic Bcl-2 family members, such as Bax, first iden-
tified as a protein that interacts with Bcl-2 (Oltvai et al., 
1993 ). The association of Bax with mitochondria is linked to 
the release of cytochrome c and other death-mediators from 45 
mitochondrial reserves (Eskes et al., 1998). 
Bax is a 21 kD protein of 192 amino acids, comprised of 
nine alpha helices (Suzuki et al., 2000). Under non-apoptotic 
conditions, Bax predominantly resides in the cytosol, with a 
small percentage of the protein localized to the mitochondria 50 
(Boohaker et al., 2011; Kaufmann et al., 2003; Putcha et al., 
1999). 
Despite advances in understanding the physiology and 
pathophysiology of cancer and/or aberrant cell growth, there 
is still a scarcity of compounds that are efficacious and safe in 55 
the treatment of cancer and/or aberrant cell growth. Thera-
peutics that are effective against bacteria and fungi are needed 
as these microorganisms grow more resistant to current thera-
pies. These needs and other needs are satisfied by the present 
Disclosed herein is a composition for permeabilizing 
membranes on or in cells comprising a CT20p peptide. 
Disclosed herein is a composition for killing cells compris-
ing a CT20p peptide. 
Disclosed herein is a composition for permeabilizing lipid 
membranes in cells comprising a CT20p peptide and one or 
more therapeutic agents, including but not limited to antibi-
otics, antimycotis, and anti-cancer drugs. 
Disclosed herein is a composition for killing cells compris-
ing a CT20p peptide and one or more therapeutic agents, 
including but not limited to antibiotics, antimycotis, and anti-
cancer drugs. 
BRIEF DESCRIPTION OF THE FIGURES 
The accompanying figures, which are incorporated in and 
constitute a part of this specification, illustrate several aspects 
and together with the description serve to explain the prin-
ciples of the invention. 
FIGS. lA and B show distribution of Bax proteins in 
lysates. FIG. lA shows that the C-terminus of wild-type Bax 
is distributed among cytosolic and mitochondria lysates (A), 
while various substitutions at the C-terminus modulates the 
invention. 
SUMMARY 
60 association of the full-length protein to the mitochondria 
(FIGS. lA and B). FIG. lC shows the results of the analysis 
of the effects of mutations in Bax demonstrating that the 
C-terminus of Bax mediates membrane permeabilization. 
Disclosed herein is a method of permeabilizing mem-
branes of cells. Such membranes may be outer membranes, 
cell membranes or interior cellular membranes. The cells may 
be individual cells or cells in a subject. Methods may com-
FIG. 2 shows that most of the DD-tagged Bax full length 
65 was found in cytosolic extracts (A), while DD-tagged CT20p 
peptide transolated to mitochondria and caused cell death (B 
andC). 
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DETAILED DESCRIPTION 
The present invention comprises methods and composi-
tions for disrupting the cellular membranes of cells. The cells 
FIG. 3 shows schematic representation of the three dimen-
sional structure of aliphatic hyperbranched nanoparticles (A), 
cells taking up nanoparticles (B) and (C) that Dil-loaded 
nanoparticles result in minimal to no cell death compared to 
the positive control (dead cells). 
FIG. 4 shows changes in cell morphology, including dis-
ruption of mitochondria, cell shrinkage and membrane per-
tubations that are indicative of cell death of Bax+/+ (A) or 
Bax-1- (B) HCT-116 cells and that cell death was measured 
and the loss of membrane integrity was detected within three 
hours of treatment with CT20 Bax peptide-nanoparticles (C). 
5 may be procaryotes or eucaryotes, and may be found as 
individual cells, in colonies, on or within multi-celled organ-
isms such as plants or animals. For example, microbial cells 
may be found on the surface of an animal, such as a human, or 
within the animal. Cancer cells may be found in a subject, 
10 
such as a plant, human or animal. 
FIG. 5 shows morphological changes in MCF-7 (A) and 
MDS-MB-231 (C) cells following treatment with CT20p 
peptide nanoparticle (A), with the loss of membrane integrity 
detected by 3 hours of treatment in MCF-7 (B) and MDS-
MB-231 (D). 
Mitochondria play a central role in regulating both apop-
totic and non-apoptotic or necrotic pathways by selectively 
releasing cell death promoting factors. The determination as 
15 to whether or not an apoptotic or non-apoptotic cell death 
pathway will be activated is dependent on the type of death 
mediator released from the mitochondria. 
FIG. 6 shows data for membrane and cellular effects of 
CT20p peptide, including that tumor cell death mediated by 
the CT20p peptide is independent of effector caspases and is 20 
resistant to Bcl-2 overexpression (A and B). FIG. 6 C-D 
shows that CT20p peptide can cause tumor regression in a 
mouse model of breast cancer. 
FIG. 7 illustrates that the DD-CT20p peptide is co-local-
ized with mitochondria (A) and these observations are quan- 25 
tified and shown in a bar graph (B). 
FIG. 8 is an immunoblot that shows the mitochondrial 
translocation ofEGFP-tagged with Bax CT (EGFP-KK) and 
K189/L190 mutants in Bax+/+ HCT-116 cells (A) and Bax_;_ 
HCT-116 cells (B). Bax+/+ HCT-116 cells (C) and Bax-1- 30 
HCT-116 cells (D) were transfected with EGFP-Kk or K189/ 
Kl 90 mutants. 
FIG. 9 shows the effect of nanoparticles alone (A) or with 
BAX peptide (B) on lipid vesicles. 
Most current anti-cancer drugs only trigger the apoptotic 
pathway. Defects in the apoptotic machinery can contribute to 
tumor formation and resistance to treatment, creating a need 
to identify anti-cancer agents that kill cells by novel mecha-
nisms. The development of a new therapeutic agent that 
induces cell death via a non-apoptotic mechanism and can be 
used in combination with standards drugs that induce apop-
tosis will have significant impact on the treatment of drug 
resistance cancers and could greatly improve overall patient 
outcomes. As described herein, the death-inducing properties 
of the C-terminal (CT) of the alpha-9 helix of Bax, an amphi-
pathic domain with putative membrane binding properties, 
were examined. 
To examine the cytotoxic potential of the CT domain of 
Bax, a peptide (CT20) was generated. The CT20p peptide 
permeabilized mitochondrial-like lipid vesicles and caused 
cell death. The cell death pathway triggered by the CT20p 
FIG. 10 shows the expression ofBcl-2 in transiently trans-
fected MDA-MB-231 cells. 
FIG. 11 shows a model for a membrane pore formed by the 
CT20 Bax peptide. Peptide molecules are shown in ribbon 
format (A). Top view of the pore formed by CT20p is shown 
in CPK format and a calcein molecule is shown within the 
pore in a ball and stick format (B). 
35 peptide was independent of effector caspases and resistant to 
Bcl-2 over-expression. This indicates that the CT20p peptide 
can be used in combinatorial therapies to sensitize drug-
resistant cancer cells to treatment. Other properties of the 
CT20 Bax peptide, show that the CT20p peptide causes cell 
FIG. 12 shows a hypothetical cell death pathway for CT20p 
peptide using a basic model of apoptotic and non-apoptotic 
cell death. 
40 membrane permeability, and such a peptide may be combined 
with antimicrobial therapeutics or therapies to cause cell 
death in microorganisms, such as gram-positive and gram-
negative bacteria, other types of bacteria, fungi and other 
microorganisms and infectious agents. 
FIG. 13 is a table ofCT20p peptide comparison with anti- 45 
microbial and apoptosis inducing peptides. 
FIG. 14 shows a graph of killing of microbial cells, a 
measure of wild type E. coli growth by optical density 
(OD280) over 24 hours with increasing concentration of 
CT20p. The inhibiting concentration (IC50) was found to be 50 
50 ug of CT20p in 100 mL LB broth. 
FIG. 15 shows a graph of killing microbial cells, a measure 
of wild type E. coli colony formation after treatment with 
both CT20p and Scrambled (SCR) peptide shows that the 
minimum inhibitory concentration (MiC) of the CT20p is 25 55 
mg. This was determined by plating the E. coli after treatment 
then counting the resulting colonies after 24 hour incubation. 
Additional advantages of the invention will be set forth in 
part in the description which follows, and in part will be 
obvious from the description, or can be learned by practice of 60 
the invention. The advantages of the invention will be realized 
and attained by means of the elements and combinations 
particularly pointed out in the appended claims. It is to be 
understood that both the foregoing general description and 
the following detailed description are exemplary and 65 
explanatory only and are not restrictive of the invention, as 
claimed. 
0001. Compositions 
Disclosed herein are compositions comprising a CT20p 
peptide. 
1. Compositions for Permeabilizing Membranes in Cells 
Disclosed herein is a composition for permeabilizing 
membranes in cells comprising a CT20p peptide. The cells 
may be individual cells, or cells that are on or in a subject. In 
an aspect, the cells are eukaryotic or prokaryotic cells, includ-
ing but not limited to bacteria and fungi. In an aspect, the cells 
are in a subject. In an aspect, the cells are on a surface, which 
may be inert or may be the surface of a subject. In an aspect, 
the cells are cancer cells or transformed cells. In an aspect, the 
cancer cell can be a cell from any type of cancer including, but 
not limited to, cancer of the head and neck cancer, esophagus, 
stomach, pancreas, kidney, bladder, bone, brain, and cervix. 
In an aspect, the cancer is breast cancer. In an aspect, the 
cancer is colorectal cancer. In an aspect, the cancer is lung 
cancer. In an aspect, the cancer is a drug resistant cancer. In an 
aspect, the cancer cell is a drug resistant cancer cell. In an 
aspect, a disclosed composition comprising a truncated Bax 
peptide is administered directly into a tumor. 
US 9,040,662 B2 
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In an aspect, a disclosed composition for permeabilizing 
membranes in cells forms one or more pores in the mem-
branes of the cells. In an aspect, the membrane may be an 
outer membrane, a cellular membrane or an organelle mem-
brane. In an aspect, the membrane is a mitochondrial mem-
brane. In an aspect, the one or more pores are formed in a 
mitochondrial membrane of a cancer cell. 
6 
peutic drugs. In an aspect, a disclosed composition compris-
ing a CT20p peptide further comprises one or more radio sen-
sitizers. 
In an aspect, a disclosed composition for permeabilizing 
membranes in cells comprising a CT20p peptide further com-
prises (i) one or more anti-cancer drugs, (ii) one or more 
chemotherapeutic drugs, and (iii) one or more radiosensitiz-
ers. In an aspect, a disclosed composition further comprises 
one or more anti-cancer drugs and one or more chemothera-
10 peutic drugs. In an aspect, a disclosed composition further 
comprises one or more anti-cancer drugs and one or more 
radio sensitizers. In an aspect, a disclosed composition further 
comprises one or more chemotherapeutic drugs and one or 
more radiosensitizers. 
In an aspect, a disclosed composition for permeabilizing 
membranes in cells destabilizes a cellular membrane. In an 
aspect, a disclosed composition facilitates ion exchange. In an 
aspect, a disclosed composition causes a sequestered mol-
ecule to be released. In an aspect, a disclosed composition 
destabilizes a cellular membrane, facilitates ion exchange, 
and causes a sequestered molecule to be released. In an 
aspect, a disclosed composition destabilizes a cellular mem- 15 
brane and facilitates ion exchange. In an aspect, a disclosed 
composition destabilizes a cellular membrane and causes a 
sequestered molecule to be released. In an aspect, a disclosed 
composition facilitates ion exchange and causes a seques-
tered molecule to be released. 20 
In an aspect, a disclosed composition for permeabilizing 
membranes in cells is administered to a subject. In an aspect, 
the subject is a manimal. In an aspect, the manimal is a 
primate. In an aspect, the mammal is a human. In an aspect, 
the human is a patient. 
In an aspect, a disclosed composition for permeabilizing 
In an aspect, a disclosed composition for permeabilizing 
membranes in cells comprising a CT20p peptide induces cell 
death. In an aspect, the cell death mimics necrosis. In an 
aspect, the cell death occurs independent of endogenous Bax 
activity. In an aspect, the cell death occurs independent of 
endogenous caspase activity. In an aspect, the cell death is 
resistant to Bcl-2 over-expression. 
In an aspect, a disclosed composition for permeabilizing 
membranes in cells comprising a CT20p peptide induces cell 
death, wherein (i) the cell death mimics necrosis, (ii) the cell 
death occurs independent of endogenous Bax activity, (iii) the 
cell death occurs independent of endogenous caspase activity, 
or (iv) the cell death is resistant to Bcl-2 over-expression, or 
(v) the cell death exhibits a combination thereof. 
In an aspect, a pore-forming composition may comprise an 
amount of a CT20p peptide so that pores comprising from two 
to ten peptides, from two to eight peptides, from four to ten 
peptides, from five, six, seven, eight, nine, ten or more pep-
tides, can be formed. 
membranes in cells comprising a CT20p peptide is adminis-
tered to a subject at least two times. In an aspect, a disclosed 
composition is administered to the subject two or more times. 
In an aspect, a disclosed composition is administered at rou-
25 tine or regular intervals. For example, in an aspect, a disclosed 
composition is administered to the subject one time per day, 
or two times per day, or three or more times per day. In an 
aspect, a disclosed composition is administered to the subject 
daily, or one time per week, or two times per week, or three or 
30 more times per week, etc. In an aspect, a disclosed composi-
tion is administered to the subject weekly, or every other 
week, or every third week, or every fourth week, etc. In an 
aspect, a disclosed composition is administered to the subject 
monthly, or every other month, or every third month, or every 
35 fourth month, etc. In an aspect, the repeated administration of 
a disclosed composition occurs over a pre-determined or defi-
nite duration of time. In an aspect, the repeated administration 
of a disclosed composition occurs over an indefinite period of 
time. 
In an aspect, a disclosed composition for permeabilizing 40 
membranes in cells comprises a CT20p peptide comprising 
SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3,and/orSEQID 
NO: 4. For example, in an aspect, a disclosed CT20p peptide 
In an aspect, following the administration of a disclosed 
composition for permeabilizing membranes in cells compris-
ing a CT20p peptide, the cells are sensitized to treatment. In 
an aspect, following the administration of a disclosed com-
position comprising a CT20p peptide, a subject is sensitized is VTIFVAGVLTASLTIWKKMG (SEQ ID NO: 1). In an 
aspect, a disclosed CT20p peptide is VTIFVAGVLTASLTI-
WEEMG (SEQ ID NO: 2). In an aspect, a disclosed CT20p 
peptide is VTIFVAGVLTASLTIWLLMG (SEQ ID NO: 3). 
In an aspect, a disclosed CT20p peptide is VTIFVAGVL-
TASLTIWRRMG (SEQ ID NO: 4). In an aspect, a disclosed 
composition for permeabilizing membranes in cells com-
prises one or more CT20 Bax peptides, wherein the one or 
more CT20 Bax peptides comprise SEQ ID NO: 1, SEQ NO: 
2, SEQ ID NO: 3; or SEQ ID NO: 4. 
In an aspect, a CT20p peptide of a disclosed composition 
for permeabilizing membranes in cells is encapsulated in 
polymeric nanoparticles. In an aspect, the nanoparticles are 
aminated. In an aspect, the nanoparticles are carboxylated. 
In an aspect, a disclosed composition for permeabilizing 
membranes in cells comprising a CT20p peptide further com-
prises one or more therapeutic compounds, such as one or 
more antimicrobial compounds, one or more antibacterial 
compounds, one or more antifungal compounds, or one or 
more anti-cancer drugs, or a combination thereof. In an 
aspect, the one or more anti-cancer drugs comprise cisplatin. 
In an aspect, the one or more anti-cancer drugs induce apop-
tosis. In an aspect, a disclosed composition comprising a 
CT20p peptide further comprises one or more chemothera-
45 to treatment. In an aspect, an increased sensitivity or a 
reduced sensitivity to a treatment, such as a therapeutic treat-
ment, is measured according to one or more methods as 
known in the art for the particular treatment. In an aspect, 
methods of measuring sensitivity to a treatment include, but 
50 not limited to, cell proliferation assays and cell death assays. 
In an aspect, the sensitivity of a cell or a subject to treatment 
can be measured or determined by comparing the sensitivity 
of a cell or a subject following administration of a disclosed 
composition comprising a CT20p peptide to the sensitivity of 
55 a cell or subject that has not been administered a disclosed 
composition comprising a CT20p peptide. 
For example, in an aspect, following the administration of 
a disclosed composition for permeabilizing membranes in 
cells comprising a CT20p peptide, the cell is 2-fold, 3-fold, 
60 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 
19-fold, 20-fold, or greater, more sensitive to treatment than a 
cell that has not been administered a disclosed composition 
comprising a CT20p peptide. In an aspect, following the 
65 administration of a disclosed composition comprising a 
CT20p peptide the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 
7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 
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14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 
or greater, less resistant to treatment than a cell that has not 
been administered a disclosed composition comprising a 
CT20p peptide. The determination of a cell's or a subject's 
sensitivity or resistance is routine in the art and within the 
skill of an ordinary clinician and/or researcher. 
In an aspect, the determination of a cell's or a subject's 
sensitivity or resistance to treatment can be monitored. For 
example, in an aspect, data regarding sensitivity or resistance 
can be acquired periodically, such as every week, every other 10 
week, every month, every other month, every 3 months, 6 
months, 9 months, or every year, every other year, every 5 
years, every 10 years for the life of the subject, for example, 
a human subject or patient with cancer and/or aberrant cell 15 
growth. In an aspect, data regarding sensitivity or resistance 
can be acquired at various rather than at periodic times. In an 
aspect, treatment for a subject can be modified based on data 
regarding a cell's or a subject's sensitivity or resistance to 
treatment. For example, in an aspect, the treatment can modi- 20 
fied by changing the dose of a disclosed compositions, the 
route of administration of a disclosed compositions, the fre-
quency of administration of a disclosed composition, etc. 
Disclosed herein is a composition for permeabilizing lipid 
membranes in cells comprising a CT20p peptide and one or 25 
more anti-cancer drugs. 
2. Compositions for Killing Cells 
Disclosed herein is a composition for killing cells compris-
ing a CT20p peptide. In an aspect, the cells are eukaryotic or 
prokaryotic cells, including but not limited to bacteria and 30 
fungi. In an aspect, the cells are in a subject. In an aspect, the 
cells are on a surface, which may be inert or may be the 
surface of a subject. In an aspect, the cells are cancer cells or 
transformed cells. In an aspect, the cancer cell can be a cell 
from any type of cancer including, but not limited to, cancer 35 
of the head and neck cancer, esophagus, stomach, pancreas, 
kidney, bladder, bone, brain, and cervix. In an aspect, the 
cancer is breast cancer. In an aspect, the cancer is colorectal 
cancer. In an aspect, the cancer is lung cancer. In an aspect, the 
cancer is a drug resistant cancer. In an aspect, the cancer cell 40 
is a drug resistant cancer cell. In an aspect, a disclosed com-
position comprising a CT20p peptide is administered directly 
into a tumor. 
8 
death occurs independent of endogenous caspase activity. In 
an aspect, the cell death is resistant to Bcl-2 over-expression. 
In an aspect, a disclosed composition for killing cells com-
prising a CT20p peptide induces cell death, wherein (i) the 
cell death mimics necrosis, (ii) the cell death occurs indepen-
dent of endogenous Bax activity, (iii) the cell death occurs 
independent of endogenous caspase activity, or (iv) the cell 
death is resistant to Bcl-2 over-expression, or (v) the cell 
death exhibits a combination thereof. 
In an aspect, a composition for killing cells comprises a 
pore-forming composition which may comprise an amount of 
a CT20p peptide so that pores comprising from two to ten 
peptides, from two to eight peptides, from four to ten pep-
tides, from five, six, seven, eight, nine, ten or more peptides, 
can be formed. 
In an aspect, a disclosed composition for killing cells com-
prises a CT20p peptide comprising SEQ ID NO: 1, SEQ ID 
NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4. For example, in 
an aspect, a disclosed CT20p peptide is VTIFVAGVL-
TASLTIWKKMG (SEQ ID NO: 1 ). In an aspect, a disclosed 
CT20p peptide is VTIFVAGVLTASLTIWEEMG (SEQ ID 
NO: 2). In an aspect, a disclosed CT20p peptide is 
VTIFVAGVLTASLTIWLLMG (SEQ ID NO: 3). In an 
aspect, a disclosed CT20p peptide is VTIFVAGVLTASLTI-
WRRMG (SEQ ID NO: 4). In an aspect, a disclosed compo-
sition for killing cells comprises one or more CT20 Bax 
peptides, wherein the one or more CT20 Bax peptides com-
prise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID 
N0:4. 
In an aspect, a CT20p peptide of a disclosed composition 
for killing cells is encapsulated in polymeric nanoparticles. In 
an aspect, the nanoparticles are aminated. In an aspect, the 
nanoparticles are carboxylated. 
In an aspect, a disclosed composition for killing cells com-
prising a CT20p peptide further comprises one or more thera-
peutic compounds, such as one or more antimicrobial com-
pounds, one or more antibacterial compounds, one or more 
antifungal compounds, or one or more anti-cancer drugs, or a 
combination thereof. In an aspect, the one or more anti-cancer 
drugs comprise cisplatin. In an aspect, the one or more anti-
cancer drugs induce apoptosis. In an aspect, a disclosed com-
position for killing cells comprising a CT20p peptide further 
comprises one or more chemotherapeutic drugs. In an aspect, 
a disclosed composition for killing cells comprising a CT20p In an aspect, a disclosed composition for killing cells forms 
one or more pores in the membranes of the cells. In an aspect, 
the membrane may be an outer membrane, a cellular mem-
brane or an organelle membrane. In an aspect, the membrane 
45 peptide further comprises one or more radiosensitizers. 
is a mitochondrial membrane. In an aspect, the one or more 
pores are formed in a mitochondrial membrane. In an aspect, 
the one or more pores are formed in a mitochondrial mem-
brane of a cancer cell. 
In an aspect, a disclosed composition for killing cells desta-
bilizes a cellular membrane. In an aspect, a disclosed com-
position facilitates ion exchange. In an aspect, a disclosed 
composition causes a sequestered molecule to be released. In 
an aspect, a disclosed composition destabilizes a cellular 
membrane, facilitates ion exchange, and causes a sequestered 
molecule to be released. In an aspect, a disclosed composition 
destabilizes a cellular membrane and facilitates ion exchange. 
In an aspect, a disclosed composition destabilizes a cellular 
membrane and causes a sequestered molecule to be released. 
In an aspect, a disclosed composition facilitates ion exchange 
and causes a sequestered molecule to be released. 
In an aspect, a disclosed composition for killing cells com-
prising a CT20p peptide induces cell death. In an aspect, the 
cell death mimics necrosis. In an aspect, the cell death occurs 
independent of endogenous Bax activity. In an aspect, the cell 
In an aspect, a disclosed composition for killing cells com-
prising a CT20p peptide further comprises (i) one or more 
anti-cancer drugs, (ii) one or more chemotherapeutic drugs, 
and (iii) one or more radiosensitizers. In an aspect, a disclosed 
50 composition for killing cells further comprises one or more 
anti-cancer drugs and one or more chemotherapeutic drugs. 
In an aspect, a disclosed composition for killing cells further 
comprises one or more anti-cancer drugs and one or more 
radiosensitizers. In an aspect, a disclosed composition for 
55 killing cells further comprises one or more chemotherapeutic 
drugs and one or more radiosensitizers. 
In an aspect, a disclosed composition for killing cells is 
administered to a subject. In an aspect, the subject is a mam-
mal. In an aspect, the mammal is a primate. In an aspect, the 
60 mammal is a human. In an aspect, the human is a patient. 
In an aspect, a disclosed composition for killing cells com-
prising a CT20p peptide is administered to a subject at least 
two times. In an aspect, a disclosed composition is adminis-
tered to the subject two or more times. In an aspect, a dis-
65 closed composition is administered at routine or regular inter-
vals. For example, in an aspect, a disclosed composition is 
administered to the subject one time per day, or two times per 
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day, or three or more times per day. In an aspect, a disclosed 
composition is administered to the subject daily, or one time 
per week, or two times per week, or three or more times per 
week, etc. In an aspect, a disclosed composition is adminis-
tered to the subject weekly, or every other week, or every third 
week, or every fourth week, etc. In an aspect, a disclosed 
composition is administered to the subject monthly, or every 
other month, or every third month, or every fourth month, etc. 
In an aspect, the repeated administration of a disclosed com-
position occurs over a pre-determined or definite duration of 10 
time. In an aspect, the repeated administration of a disclosed 
composition occurs over an indefinite period of time. 
In an aspect, following the administration of a disclosed 
composition for killing cells comprising a CT20p peptide, the 15 
cells are sensitized to treatment. In an aspect, following the 
administration of a disclosed composition for killing cells 
comprising a CT20p peptide, a subject is sensitized to treat-
ment. In an aspect, an increased sensitivity or a reduced 
sensitivity to a treatment, such as a therapeutic treatment, is 20 
measured according to one or more methods as known in the 
art for the particular treatment. In an aspect, methods of 
measuring sensitivity to a treatment include, but not limited 
to, cell proliferation assays and cell death assays. In an aspect, 
the sensitivity of a cell or a subject to treatment can be mea- 25 
sured or determined by comparing the sensitivity of a cell or 
a subject following administration of a disclosed composition 
for killing cells comprising a CT20p peptide to the sensitivity 
of a cell or subject that has not been administered a disclosed 
composition for killing cells comprising a CT20p peptide. 30 
For example, in an aspect, following the administration of 
a disclosed composition for killing cells comprising a CT20p 
peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 
7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 35 
14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 
10 
3. Pharmaceutical Compositions 
In an aspect, the invention relates to pharmaceutical com-
positions comprising a disclosed composition for permeabi-
lizing membranes in cells. In an aspect, the invention relates 
to pharmaceutical compositions comprising a disclosed com-
position for killing cells. In an aspect, the disclosed compo-
sitions for permeabilizing membranes and cells and for kill-
ing cells comprise a CT20 Bax peptide. In an aspect, a 
pharmaceutical composition can be provided comprising a 
therapeutically effective amount of at least one disclosed 
composition and a pharmaceutically acceptable carrier. 
0002. Methods Comprising a Disclosed Composition 
1. Permeabilizing Membranes of Cells 
Disclosed herein are methods of permeabilizing mem-
branes of cells. The cells may be individual cells, or cells that 
are on or in a subject. In an aspect, the cells are eukaryotic or 
prokaryotic cells, including but not limited to bacteria and 
fungi. 
In an aspect, disclosed herein is a method of permeabiliz-
ing membranes of cells in a subject comprising administering 
to at least a cell a CT20p peptide. In an aspect, disclosed 
herein is a method of permeabilizing membranes of cells in a 
subject comprising administering to at least a cell a compo-
sition comprising an effective amount of a CT20p peptide. In 
an aspect, the membrane may be an outer membrane, a cel-
lular membrane or an organelle membrane. In an aspect the 
cell is a bacterial cell. In an aspect, the cell is a fungal cell. In 
an aspect, the cell is a microbial cell. In an aspect, the cell is 
a cancer cell or a transformed cell. In an aspect, the cancer cell 
can be a cell from any type of cancer including, but not limited 
to, cancer of the head and neck cancer, esophagus, stomach, 
pancreas, kidney, bladder, bone, brain, and cervix. In an 
aspect, the cancer is breast cancer. In an aspect, the cancer is 
colorectal cancer. In an aspect, the cancer is lung cancer. In an 
aspect, the cancer is a drug resistant cancer. In an aspect, the 
cancer cell is a drug resistant cancer cell. In an aspect, a 
CT20p peptide or a composition comprising an effective 
40 amount of a CT20p peptide is administered directly into a 
or greater, more sensitive to treatment than a cell that has not 
been administered a disclosed composition for killing cells 
comprising a CT20p peptide. In an aspect, following the 
administration of a disclosed composition for killing cells 
comprising a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 
5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 
19-fold, 20-fold, or greater, less resistant to treatment than a 
cell that has not been administered a disclosed composition 45 
for killing cells comprising a CT20p peptide. The determina-
tion of a cell's or a subject's sensitivity or resistance is routine 
in the art and within the skill of an ordinary clinician and/or 
researcher. 
In an aspect, the determination of a cell's or a subject's 50 
sensitivity or resistance to treatment can be monitored. For 
example, in an aspect, data regarding sensitivity or resistance 
can be acquired periodically, such as every week, every other 
week, every month, every other month, every 3 months, 6 
months, 9 months, or every year, every other year, every 5 55 
years, every 10 years for the life of the subject, for example, 
tumor. 
In an aspect of a disclosed a method of permeabilizing 
membranes of cells, a CT20p peptide or a composition com-
prising an effective amount of a CT20p peptide forms at least 
one pore in the membrane of the cell. In an aspect, a CT20p 
peptide or a composition comprising an effective amount of a 
CT20p peptide forms two or more pores in the membrane of 
the cell. In an aspect, cell is a cancer cell. In an aspect, the one 
or more pores are formed in a mitochondrial membrane. In an 
aspect, the one or more pores are formed in a mitochondrial 
membrane of a cancer cell. 
In an aspect of a disclosed method of permeabilizing mem-
branes of cells in a subject, a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide destabi-
lizes a cellular membrane, facilitates ion exchange, and 
causes a sequestered molecule to be released. In an aspect, a 
CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide destabilizes a cellular membrane. 
In an aspect, a CT20p peptide or a composition comprising an 
effective amount of a CT20p peptide facilitates ion exchange, 
exchange. In an aspect, a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide causes a 
sequestered molecule to be released. In an aspect, a CT20p 
peptide or a composition comprising an effective amount of a 
a human subject or patient with cancer and/or aberrant cell 
growth. In an aspect, data regarding sensitivity or resistance 
can be acquired at various rather than at periodic times. In an 
aspect, treatment for a subject can be modified based on data 60 
regarding a cell's or a subject's sensitivity or resistance to 
treatment. For example, in an aspect, the treatment can modi-
fied by changing the dose of a disclosed compositions, the 
route of administration of a disclosed compositions, the fre-
quency of administration of a disclosed composition, etc. 65 CT20p peptide destabilizes a cellular membrane and facili-
tates ion exchange. In an aspect, a CT20p peptide or a com-
position comprising an effective amount of a CT20p peptide 
Disclosed herein is a composition for killing cells compris-
ing a CT20p peptide and one or more anti-cancer drugs. 
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destabilizes a cellular membrane and causes a sequestered 
molecule to be released. In an aspect, a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide facilitates ion exchange and causes a sequestered 
molecule to be released. 
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administered to the subject two or more times. In an aspect, a 
CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide administered at routine or regular 
intervals. For example, in an aspect, a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide is administered to the subject one time per day, or two 
times per day, or three or more times per day. In an aspect, a 
CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide is administered to the subject 
In an aspect, following the administration of a CT20p 
peptide or a composition comprising an effective amount of a 
CT20p peptide, the cells are sensitized to treatment. In an 
aspect, following the administration of CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide, a subject is sensitized to treatment. In an aspect, an 
increased sensitivity or a reduced sensitivity to a treatment, 
such as a therapeutic treatment, is measured according to one 
or more methods as known in the art for the particular treat-
ment. In an aspect, methods of measuring sensitivity to a 
treatment include, but not limited to, cell proliferation assays 
and cell death assays. In an aspect, the sensitivity of a cell or 
10 daily, or one time per week, or two times per week, or three or 
more times per week, etc. In an aspect, a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide is administered to the subject weekly, or every other 
week, or every third week, or every fourth week, etc. In an 
a subject to treatment can be measured or determined by 
comparing the sensitivity of a cell or a subject following 
administration of a CT20p peptide or a composition compris-
ing an effective amount of a CT20p peptide to the sensitivity 
of a cell or subject that has not been administered a CT20p 
peptide or a composition comprising an effective amount of a 
CT20p peptide. 
15 aspect, a CT20p peptide or a composition comprising an 
effective amount of a CT20p peptide is administered to the 
subject monthly, or every other month, or every third month, 
or every fourth month, etc. In an aspect, the repeated admin-
istration of a CT20p peptide or a composition comprising an 
20 effective amount of a CT20p peptide occurs over a pre-deter-
mined or definite duration of time. In an aspect, the repeated 
administration of a CT20p peptide or a composition compris-
ing an effective amount of a CT20p peptide occurs over an 
indefinite period of time. 
In an aspect, a disclosed method of permeabilizing mem-
branes of cells in a subject further comprises inducing cell 
death. In an aspect, cell death mimics necrosis. In an aspect, 
cell death occurs independent of endogenous Bax activity. In 
an aspect, cell death occurs independent of endogenous 
For example, in an aspect, following the administration of 25 
a CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 
5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 
19-fold, 20-fold, or greater, more sensitive to treatment than a 
cell that has not been administered a CT20p peptide or a 
disclosed composition comprising an effective amount of a 
CT20p peptide. In an aspect, following the administration of 
30 caspase activity. In an aspect, cell death is resistant to Bcl-2 
a CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 35 
5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 
19-fold, 20-fold, or greater, less resistant to treatment than a 
cell that has not been administered a CT20p peptide or a 
disclosed composition comprising an effective amount of a 40 
CT20p peptide. The determination of a cell's or a subject's 
sensitivity or resistance is routine in the art and within the 
skill of an ordinary clinician and/or researcher. 
In an aspect, the determination of a cell's or a subject's 
sensitivity or resistance to treatment can be monitored. For 45 
example, in an aspect, data regarding sensitivity or resistance 
can be acquired periodically, such as every week, every other 
week, every month, every other month, every 3 months, 6 
months, 9 months, or every year, every other year, every 5 
years, every 10 years for the life of the subject, for example, 50 
a human subject or patient with cancer and/or aberrant cell 
growth. In an aspect, data regarding sensitivity or resistance 
can be acquired at various rather than at periodic times. In an 
aspect, treatment for a subject can be modified based on data 
regarding a cell's or a subject's sensitivity or resistance to 55 
treatment. For example, in an aspect, the treatment can modi-
fied by changing the dose of a disclosed compositions, the 
route of administration of a disclosed compositions, the fre-
quency of administration of a disclosed composition, etc. 
In an aspect, a disclosed method of permeabilizing mem- 60 
branes of cells in a subject further comprises repeating the 
administration a CT20p peptide or a composition comprising 
an effective amount of a CT20p peptide. In an aspect, a 
CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide is administered to the subject at 65 
least two times. In an aspect, a CT20p peptide or a composi-
tion comprising an effective amount of a CT20p peptide is 
over-expression. 
In an aspect, a disclosed method of permeabilizing mem-
branes of cells in a subject comprising administering a CT20p 
peptide or a composition comprising an effective amount of a 
CT20p peptide further comprises inducing cell death. Cell 
death may include, but is not limited to wherein (i) cell death 
mimics necrosis, (ii) cell death occurs independent of endog-
enous Bax activity, (iii) cell death occurs independent of 
endogenous caspase activity, or (iv) cell death is resistant to 
Bcl-2 over-expression, or (v) cell death exhibits a combina-
tion thereof. 
In an aspect, a CT20p peptide or a composition comprising 
an effective amount of a CT20p peptide of a disclosed method 
of permeabilizing cell membranes comprises SEQ ID NO: 1, 
SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4. For 
example, in an aspect, a CT20p peptide is VTIFVAGVL-
TASLTIWKKIVIG (SEQ ID NO: 1). In an aspect, a CT20p 
peptide is VTIFVAGVLTASLTIWEEMG (SEQ ID NO: 2). 
In an aspect, a CT20p peptide is VTIFVAGVLTASLTI-
WLLMG (SEQ ID NO: 3). In an aspect, a CT20p peptide is 
VTIFVAGVLTASLTIWRRMG (SEQ ID NO: 4). In an 
aspect, a disclosed composition comprising an effective 
amount of a CT20p peptide comprises one or more CT20 Bax 
peptides, wherein the one or more CT20 Bax peptides com-
prise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID 
NO: 4, or two or more of each. In an aspect, a CT20p peptide 
of a disclosed method of permeabilizing membranes of cells 
in a subject is encapsulated in polymeric nanoparticles. In an 
aspect, the nanoparticles are aminated. In an aspect, the nano-
particles are carboxylated. 
In an aspect, a disclosed method of permeabilizing mem-
branes comprising administering a CT20p peptide or a com-
position comprising an effective amount of a CT20p peptide 
further comprises administering one or more anti-cancer 
drugs. In an aspect, the one or more anti-cancer drugs com-
prise cisplatin. In an aspect, the one or more anti-cancer drugs 
induce apoptosis. In an aspect, a disclosed method of perme-
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abilizing membranes compnsmg administering a CT20p 
peptide or a composition comprising an effective amount of a 
CT20p peptide further comprises administering one or more 
chemotherapeutic drugs. In an aspect, a disclosed method of 
permeabilizing membranes comprising administering a 
CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide further comprises administering 
one or more radiosensitizers. 
14 
lizing at least one membrane in the cell comprises causing a 
sequestered molecule to be released. In an aspect, permeabi-
lizing at least one membrane in the cell comprises destabiliz-
ing a cellular membrane and facilitating ion exchange. In an 
aspect, permeabilizing at least one membrane in the cell 
comprises destabilizing a cellular membrane and causing a 
sequestered molecule to be released. In an aspect, permeabi-
lizing at least one membrane in the cell comprises facilitating 
ion exchange and causing a sequestered molecule to be In an aspect, a disclosed method of permeabilizing mem-
branes comprising administering a CT20p peptide or a com-
position comprising an effective amount of a CT20p peptide 
further comprises administering (i) one or more anti-cancer 
drugs, (ii) one or more chemotherapeutic drugs, and (iii) one 
10 released. 
or more radiosensitizers. In an aspect, a disclosed method 
further comprises administering one or more anti-cancer 15 
drugs and one or more chemotherapeutic drugs. In an aspect, 
a disclosed method further comprises administering one or 
more anti-cancer drugs and one or more radiosensitizers. In 
an aspect, a disclosed method further comprises administer-
ing one or more chemotherapeutic drugs and one or more 20 
radio sensitizers. 
In an aspect of a disclosed method of permeabilizing mem-
branes of cells, which may be in or on a subject, the subject is 
a manmial. In an aspect, the mammal is a primate. In an 
aspect, the manmial is a human. In an aspect, the human is a 25 
patient. 
In an aspect, disclosed herein is a method of permeabiliz-
ing membranes of cells in a subject comprising (i) adminis-
tering to a subject an effective amount of a CT20p peptide or 
a composition comprising an effective amount of a CT20p 30 
peptide, and (ii) forming at least one pore in a membrane of at 
least one cell of the subject, wherein the peptide destabilizes 
at least one membrane, facilitates ion exchange, and/or causes 
a sequestered molecule to be released. 
In an aspect of a disclosed method of killing cancer cells in 
a subject, the cancer cells are sensitized to treatment. In an 
aspect of a disclosed method of killing cancer cells in a 
subject, the subject is sensitized to treatment. In an aspect, an 
increased sensitivity or a reduced sensitivity to a treatment, 
such as a therapeutic treatment, is measured according to one 
or more methods as known in the art for the particular treat-
ment. In an aspect, methods of measuring sensitivity to a 
treatment include, but not limited to, cell proliferation assays 
and cell death assays. In an aspect, the sensitivity of a cell or 
a subject to treatment can be measured or determined by 
comparing the sensitivity of a cell or a subject following 
administration of a CT20p peptide or a composition compris-
ing a CT20p peptide to the sensitivity of a cell or subject that 
has not been administered a CT20p peptide or a composition 
comprising a CT20p peptide. 
For example, in an aspect, following the administration of 
a CT20p peptide or a composition comprising a CT20p pep-
tide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 
8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 
15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, or 
greater, more sensitive to treatment than a cell that has not 
been administered a CT20p peptide or a composition com-
prising a CT20p peptide. In an aspect, following the admin-
2. Killing Cancer Cells 
Disclosed herein are methods of killing cancer cells. 
In an aspect, disclosed herein is a method of killing cancer 
cells in a subject comprising administering to at least one cell 
35 istration of a CT20p peptide or a composition comprising a 
CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 
6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 
13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 
of a subject an effective amount of a CT20p peptide. In an 
aspect, disclosed herein is a method of killing cancer cells in 40 
a subject comprising administering to at least one cell of a 
subject a composition comprising an effective amount of a 
CT20p peptide. In an aspect, the cell is a cancer cell or a 
transformed cell. In an aspect, the cancer cell can be a cell 
from any type of cancer including, but not limited to, cancer 45 
of the head and neck cancer, esophagus, stomach, pancreas, 
kidney, bladder, bone, brain, and cervix. In an aspect, the 
cancer is breast cancer. In an aspect, the cancer is colorectal 
cancer. In an aspect, the cancer is lung cancer. In an aspect, the 
cancer is a drug resistant cancer. In an aspect, the cancer cell 50 
is a drug resistant cancer cell. In an aspect, a CT20p peptide 
or a composition comprising an effective amount of a CT20p 
peptide is administered directly into a tumor. 
20-fold, or greater, less resistant to treatment than a cell that 
has not been administered a CT20p peptide or a composition 
comprising a CT20p peptide. The determination of a cell's or 
a subject's sensitivity or resistance is routine in the art and 
within the skill of an ordinary clinician and/or researcher. 
In an aspect, the determination of a cell's or a subject's 
sensitivity or resistance to treatment can be monitored. For 
example, in an aspect, data regarding sensitivity or resistance 
can be acquired periodically, such as every week, every other 
week, every month, every other month, every 3 months, 6 
months, 9 months, or every year, every other year, every 5 
years, every 10 years for the life of the subject, for example, 
a human subject or patient with cancer and/or aberrant cell 
growth. In an aspect, data regarding sensitivity or resistance 
can be acquired at various rather than periodic times. In an 
aspect, treatment for a subject can be modified based on data 
regarding a cell's or a subject's sensitivity or resistance to 
treatment. 
In an aspect, a disclosed method of killing cancer cells in a 
subject further comprises repeating the administration of a 
CT20p peptide or a composition comprising an effective 
In an aspect, a disclosed method of killing cancer cells in a 
subject further comprises permeabilizing at least one mem- 55 
brane in the cell. In an aspect, the membrane is a mitochon-
drial membrane. In an aspect, the one or more pores are 
formed in a mitochondrial membrane. In an aspect, the one or 
more pores are formed in a mitochondrial membrane of a 
cancer cell. 60 amount of a CT20p peptide. In an aspect, a CT20p peptide or 
a composition comprising an effective amount of a CT20p 
peptide is administered to the subject at least two times. In an 
aspect, a CT20p peptide or a composition comprising an 
effective amount of a CT20p peptide is administered to the 
In an aspect, permeabilizing at least one membrane in the 
cell comprises destabilizing a cellular membrane, facilitating 
ion exchange, and causing a sequestered molecule to be 
released. In an aspect, permeabilizing at least one membrane 
in the cell comprises destabilizes a cellular membrane. In an 
aspect, permeabilizing at least one membrane in the cell 
comprises facilitating ion exchange. In an aspect, permeabi-
65 subject two or more times. In an aspect, a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide is administered at routine or regular intervals. For 
US 9,040,662 B2 
15 
example, in an aspect, a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide is admin-
istered to the subject one time per day, or two times per day, 
or three or more times per day. In an aspect, a CT20p peptide 
or a composition comprising an effective amount of a CT20p 
peptide is administered to the subject daily, or one time per 
week, or two times per week, or three or more times per week, 
etc. In an aspect, a CT20p peptide or a composition compris-
ing an effective amount of a CT20p peptide is administered to 
the subject weekly, or every other week, or every third week, 
or every fourth week, etc. In an aspect, a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide is administered to the subject monthly, or every other 
month, or every third month, or every fourth month, etc. In an 
aspect, the repeated administration of a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide occurs over a pre-determined or definite duration of 
time. In an aspect, the repeated administration of a CT20p 
peptide or a composition comprising an effective amount of a 
CT20p peptide occurs over an indefinite period of time. 
In an aspect, a disclosed method of killing cancer cells in a 
subject further comprises inducing cell death. In an aspect, 
cell death mimics necrosis. In an aspect, cell death occurs 
independent of endogenous Bax activity. In an aspect, cell 
death occurs independent of endogenous caspase activity. In 
an aspect, cell death is resistant to Bcl-2 over-expression. In 
an aspect, a disclosed method of killing cancer cells induces 
cell death, wherein (i) cell death mimics necrosis, (ii) cell 
death occurs independent of endogenous Bax activity, (iii) 
cell death occurs independent of endogenous caspase activity, 
or (iv) cell death is resistant to Bcl-2 over-expression, or (v) 
cell death exhibits a combination thereof. 
In an aspect, a CT20p peptide of a disclosed method of 
killing cells comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ 
16 
comprises administering (i) one or more anti-cancer drugs, 
(ii) one or more chemotherapeutic drugs, and (iii) one or more 
radiosensitizers. In an aspect, a disclosed method for killing 
cancer cells further comprises administering one or more 
anti-cancer drugs and one or more chemotherapeutic drugs. 
In an aspect, a disclosed method for killing cancer cells fur-
ther comprises administering one or more anti-cancer drugs 
and one or more radiosensitizers. In an aspect, a disclosed 
method for killing cancer cells further comprises administer-
10 ing one or more chemotherapeutic drugs and one or more 
radio sensitizers. 
In an aspect of a disclosed method of killing cancer cells in 
a subject, the subject is a manimal. In an aspect, the mammal 
is a primate. In an aspect, the mammal is a human. In an 
15 aspect, the human is a patient. 
20 
Disclosed herein is a method of killing cancer cells in a 
subject comprising (i) administering to a subject an effective 
amount of a CT20p peptide, (ii) permeabilizing at least one 
membrane in a cell of the subject, and (iii) inducing cell death. 
3. Killing Cancer Cells 
Disclosed herein are methods of killing microbial cells. 
In an aspect, disclosed herein is a method of killing micro-
bial cells in a subject comprising administering to at least one 
cell of a subject an effective amount of a CT20p peptide. In an 
25 aspect, disclosed herein is a method of killing microbial cells 
in a subject comprising administering to at least one cell of a 
subject a composition comprising an effective amount of a 
CT20p peptide. In an aspect, the cell is a microbial cell, 
including eukaryotic and prokaryotic cells, such as bacteria 
30 and/or fungi. Inan aspect, the cell is a drug resistant microbial 
cell. In an aspect, a CT20p peptide or a composition compris-
ing an effective amount of a CT20p peptide is administered 
directly. 
In an aspect, a disclosed method of killing microbial cells 
35 in a subject further comprises permeabilizing at least one 
membrane in the cell. In an aspect, the membrane is a mito-
chondrial membrane. In an aspect, the one or more pores are 
formed in a mitochondrial membrane. In an aspect, the one or 
more pores are formed in a mitochondrial membrane of a 
ID NO: 3, and/or SEQ ID NO: 4. For example, in an aspect, a 
C-terminal truncated Bax is VTIFVAGVLTASLTIWKKMG 
(SEQ ID NO: 1 ). In an aspect, a CT20p peptide is 
VTIFVAGVLTASLTIWEEMG (SEQ ID NO: 2). In an 
aspect, a CT20p peptide is VTIFVAGVLTASLTIWLLMG 
(SEQ ID NO: 3). In an aspect, a CT20p peptide is 
VTIFVAGVLTASLTIWRRMG (SEQ ID NO: 4). In an 
aspect, a disclosed composition comprising an effective 
amount of a CT20p peptide comprises one or more CT20 Bax 
peptides, wherein the one or more CT20 Bax peptides com-
prise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID 45 
N0:4. 
40 microbial cell. 
In an aspect, permeabilizing at least one membrane in the 
cell comprises destabilizing a cellular membrane, facilitating 
ion exchange, and causing a sequestered molecule to be 
released. In an aspect, permeabilizing at least one membrane 
in the cell comprises destabilizes a cellular membrane. In an 
aspect, permeabilizing at least one membrane in the cell 
In an aspect, a CT20p peptide of a disclosed method of 
killing cancer cells in a subject is encapsulated in polymeric 
nanoparticles. In an aspect, the nanoparticles are aminated. In 
an aspect, the nanoparticles are carboxylated. 
In an aspect, a disclosed method for killing cancer cells 
comprising administering a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide further 
comprises administering one or more anti-cancer drugs. In an 
aspect, the one or more anticancer drugs comprise cisplatin. 
In an aspect, the one or more anti-cancer drugs induce apop-
tosis. In an aspect, a disclosed method for killing cancer cells 
comprising administering a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide further 
comprises administering one or more chemotherapeutic 
drugs. In an aspect, a disclosed method for killing cancer cells 
comprising administering a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide further 
comprises administering one or more radiosensitizers. 
In an aspect, a disclosed method for killing cancer cells 
comprising administering a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide further 
comprises facilitating ion exchange. In an aspect, permeabi-
lizing at least one membrane in the cell comprises causing a 
sequestered molecule to be released. In an aspect, permeabi-
50 lizing at least one membrane in the cell comprises destabiliz-
ing a cellular membrane and facilitating ion exchange. In an 
aspect, permeabilizing at least one membrane in the cell 
comprises destabilizing a cellular membrane and causing a 
sequestered molecule to be released. In an aspect, permeabi-
55 lizing at least one membrane in the cell comprises facilitating 
ion exchange and causing a sequestered molecule to be 
released. 
In an aspect of a disclosed method ofkilling microbial cells 
in a subject, the microbial cells are sensitized to treatment. In 
60 an aspect of a disclosed method of killing microbial cells in a 
subject, the subject is sensitized to treatment. In an aspect, an 
increased sensitivity or a reduced sensitivity to a treatment, 
such as a therapeutic treatment, is measured according to one 
or more methods as known in the art for the particular treat-
65 ment. In an aspect, methods of measuring sensitivity to a 
treatment include, but not limited to, cell proliferation assays 
and cell death assays. In an aspect, the sensitivity of a cell or 
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a subject to treatment can be measured or determined by 
comparing the sensitivity of a cell or a subject following 
administration of a CT20p peptide or a composition compris-
ing a CT20p peptide to the sensitivity of a cell or subject that 
has not been administered a CT20p peptide or a composition 
comprising a CT20p peptide. 
For example, in an aspect, following the administration of 
a CT20p peptide or a composition comprising a CT20p pep-
tide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 
8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, lO 
15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, or 
18 
In an aspect, a disclosed method of killing microbial cells 
in a subject further comprises inducing cell death. In an 
aspect, cell death mimics necrosis. In an aspect, cell death 
occurs independent of endogenous Bax activity. In an aspect, 
cell death occurs independently of endogenous caspase activ-
ity. In an aspect, cell death is resistant to Bcl-2 over-expres-
sion. In an aspect, a disclosed method of killing cells induces 
cell death, wherein (i) cell death mimics necrosis, (ii) cell 
death occurs independent of endogenous Bax activity, (iii) 
cell death occurs independent of endogenous caspase activity, 
or (iv) cell death is resistant to Bcl-2 over-expression, or (v) 
cell death exhibits a combination thereof. 
In an aspect, a CT20p peptide of a disclosed method of 
killing cells comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ 
greater, more sensitive to treatment than a cell that has not 
been administered a CT20p peptide or a composition com-
prising a CT20p peptide. In an aspect, following the admin-
istration of a CT20p peptide or a composition comprising a 
CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 
6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 
13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 
20-fold, or greater, less resistant to treatment than a cell that 
has not been administered a CT20p peptide or a composition 
comprising a CT20p peptide. The determination of a cell's or 
15 ID NO: 3, and/or SEQ ID NO: 4. For example, in an aspect, a 
C-terminal truncated Bax is VTIFVAGVLTASLTIWKKMG 
(SEQ ID NO: 1). In an aspect, a CT20p peptide is 
VTIFVAGVLTASLTIWEEMG (SEQ ID NO: 2). In an 
aspect, a CT20p peptide is VTIFVAGVLTASLTIWLLMG 
a subject's sensitivity or resistance is routine in the art and 
within the skill of an ordinary clinician and/or researcher. 
20 (SEQ ID NO: 3). In an aspect, a CT20p peptide is 
VTIFVAGVLTASLTIWRRMG (SEQ ID NO: 4). In an 
aspect, a disclosed composition comprising an effective 
amount of a CT20p peptide comprises one or more CT20 Bax 
peptides, wherein the one or more CT20 Bax peptides com-
25 prise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID 
N0:4. 
In an aspect, the determination of a cell's or a subject's 
sensitivity or resistance to treatment can be monitored. For 
example, in an aspect, data regarding sensitivity or resistance 
can be acquired periodically, such as every week, every other 
week, every month, every other month, every 3 months, 6 
months, 9 months, or every year, every other year, every 5 30 
years, every 10 years for the life of the subject, for example, 
a human subject. In an aspect, data regarding sensitivity or 
resistance can be acquired at various rather than periodic 
times. In an aspect, treatment for a subject can be modified 
based on data regarding a cell's or a subject's sensitivity or 35 
resistance to treatment. 
In an aspect, a disclosed method of killing microbial cells 
in a subject further comprises repeating the administration of 
In an aspect, a CT20p peptide of a disclosed method of 
killing microbial cells in a subject is encapsulated in poly-
meric nanoparticles. In an aspect, the nanoparticles are ami-
nated. In an aspect, the nanoparticles are carboxylated. 
In an aspect, a disclosed method for killing microbial cells 
comprising administering a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide further 
comprises administering one or more anti-microbial drugs. In 
an aspect, a disclosed method for killing microbial cells com-
prising administering a CT20p peptide or a composition com-
prising an effective amount of a CT20p peptide further com-
prises administering one or more chemotherapeutic drugs. In 
an aspect, a disclosed method for killing cancer cells com-a CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide. In an aspect, a CT20p peptide or 
a composition comprising an effective amount of a CT20p 
peptide is administered to the subject at least two times. In an 
aspect, a CT20p peptide or a composition comprising an 
effective amount of a CT20p peptide is administered to the 
subject two or more times. In an aspect, a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide is administered at routine or regular intervals. For 
example, in an aspect, a CT20p peptide or a composition 
comprising an effective amount of a CT20p peptide is admin-
istered to the subject one time per day, or two times per day, 
40 prising administering a CT20p peptide or a composition com-
prising an effective amount of a CT20p peptide further com-
prises administering one or more antimicrobial therapeutics 
or therapies. 
In an aspect of a disclosed method ofkilling microbial cells 
45 in or on a subject, the subject is a mammal. In an aspect, the 
mammal is a primate. In an aspect, the mammal is a human. In 
an aspect, the human is a patient. 
or three or more times per day. In an aspect, a CT20p peptide 
Disclosed herein is a method of killing microbial cells in a 
subject comprising (i) administering to a subject an effective 
50 amount of a CT20p peptide, (ii) permeabilizing at least one 
membrane in a cell of the subject, and (iii) inducing cell death. 
4. Other Uses or a composition comprising an effective amount of a CT20p 
peptide is administered to the subject daily, or one time per 
week, or two times per week, or three or more times per week, 
etc. In an aspect, a CT20p peptide or a composition compris- 55 
ing an effective amount of a CT20p peptide is administered to 
the subject weekly, or every other week, or every third week, 
or every fourth week, etc. In an aspect, a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide is administered to the subject monthly, or every other 60 
month, or every third month, or every fourth month, etc. In an 
aspect, the repeated administration of a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide occurs over a pre-determined or definite duration of 
time. In an aspect, the repeated administration of a CT20p 65 
peptide or a composition comprising an effective amount of a 
CT20p peptide occurs over an indefinite period of time. 
Also disclosed herein are uses of a disclosed composition 
as an investigational and/or research tool in the development 
and standardization of in vitro and in vivo test systems for 
evaluation in laboratory animals such as cats, dogs, rabbits, 
monkeys, rats and mice, as part of the search for (i) new 
therapeutic approaches for permeabilizing membranes of 
cells and for killing cancerormicrobial cells as well as (ii) the 
evaluation of the permeabilization of membranes of cells and 
for the killing of cancer or microbial cells. In an aspect, the 
search for new therapeutic approaches and the evaluation of 
new therapeutic approaches involves a subject, such as a 
human subject or human patient. 
Methods ofkilling microbial organisms on an inert surface. 
The present invention comprises methods of treating a 
surface to render it antimicrobial, comprising contacting a 
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CT20p peptide composition comprising CT20p peptide to a 
surface. The peptides may be air-dried and remain on the 
surface or may be affixed to the surface by binding to other 
proteins or binding-partners on the surface, or may be 
attached by adhesive compounds or other compounds known 
for attaching proteins to a surface, or the peptides may remain 
in solution in a liquid or semisolid or other form that contacts 
the surface. The CT20p peptide composition may comprise 
SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3,and/orSEQID 
NO: 4, or a combination of two or more of SEQ ID NOs 1-4. 
When a surface treated with a CT20p peptide composition 
comprising one or more CT20p peptides is then contacted by 
microbial organisms, it is believed that the cellular mem-
branes of the microbial organisms are permeabilized and 
microbial death may occur. 
0003. Definitions 
Unless otherwise expressly stated, it is in no way intended 
that any method or aspect set forth herein be construed as 
requiring that its steps be performed in a specific order. 
Accordingly, where a method claim does not specifically state 
in the claims or descriptions that the steps are to be limited to 
a specific order, it is no way intended that an order be inferred, 
in any respect. This holds for any possible non-express basis 
for interpretation, including matters of logic with respect to 
arrangement of steps or operational flow, plain meaning 
derived from grammatical organization or punctuation, or the 
number or type of aspects described in the specification. 
As used in the specification and the appended claims, the 
singular forms "a," "an" and "the" include plural referents 
unless the context clearly dictates otherwise. 
The word "or" as used herein means any one member of a 
particular list and also includes any combination of members 
of that list. 
20 
In general, the biological activity or biological action of a 
peptide refers to any function exhibited or performed by the 
peptide that is ascribed to the naturally occurring form of the 
peptide as measured or observed in vivo (i.e., in the natural 
physiological environment of the protein) or in vitro (i.e., 
under laboratory conditions). For example, a biological activ-
ity of the CT20p peptide is the cytotoxic activity of the CT20 
Bax peptide. 
Theterm "enzyme" as used herein refers to any peptide that 
10 
catalyzes a chemical reaction of other substances without 
itself being destroyed or altered upon completion of the reac-
tion. Typically, a peptide having enzymatic activity catalyzes 
the formation of one or more products from one or more 
15 substrates. Such peptides can have any type of enzymatic 
activity including, without limitation, the enzymatic activity 
or enzymatic activities associated with enzymes such as those 
disclosed herein. 
References in the specification and concluding claims to 
20 parts by weight of a particular element or component in a 
composition denotes the weight relationship between the ele-
ment or component and any other elements or components in 
the composition or article for which a part by weight is 
expressed. Thus, in a compound containing 2 parts by weight 
25 of component X and 5 parts by weight component Y, X and Y 
are present at a weight ratio of 2:5, and are present in such 
ratio regardless of whether additional components are con-
tained in the compound. 
A weight percent (wt. % ) of a component, unless specifi-
30 cally stated to the contrary, is based on the total weight of the 
formulation or composition in which the component is 
included. 
As used herein, the terms "optional" or "optionally" means 
that the subsequently described event or circumstance can or 
35 can not occur, and that the description includes instances 
where said event or circumstance occurs and instances where 
it does not. 
Ranges can be expressed herein as from "about" one par-
ticular value, and/or to "about" another particular value. 
When such a range is expressed, a further aspect includes 
from the one particular value and/or to the other particular 
value. Similarly, when values are expressed as approxima- 40 
tions, by use of the antecedent "about," it will be understood 
that the particular value forms a further aspect. It will be 
further understood that the endpoints of each of the ranges are 
significant both in relation to the other endpoint, and inde-
pendently of the other endpoint. It is also understood that 45 
there are a number of values disclosed herein, and that each 
value is also herein disclosed as "about" that particular value 
As used herein, the terms "transformation" and "transfec-
tion" mean the introduction of a nucleic acid, e.g., an expres-
sion vector, into a recipient cell including introduction of a 
nucleic acid to the chromosomal DNA of said cell. The art is 
familiar with various compositions, methods, techniques, etc. 
used to effect the introduction of a nucleic acid into a recipient 
cell. The art is familiar with such compositions, methods, 
techniques, etc for both eukaryotic and prokaryotic cells. The 
art is familiar with such compositions, methods, techniques, 
etc. forthe optimization of the introduction and expression of 
a nucleic acid into and within a recipient cell. in addition to the value itself. For example, ifthe value "10" 
is disclosed, then "about 10" is also disclosed. It is also 
understood that each unit between two particular units are 50 
also disclosed. For example, if 10 and 15 are disclosed, then 
11, 12, 13, and 14 are also disclosed. 
As used herein, the amino acid abbreviations are conven-
tional one letter codes for the amino acids and are expressed 
as follows: A, alanine; B, asparagine or aspartic acid; C, 55 
cysteine; D aspartic acid; E, glutamate, glutamic acid; F, 
phenylalanine; G, glycine; H histidine; I isoleucine; K, 
lysine; L, leucine; M, methionine; N, asparagine; P, praline; 
As used herein, "a CT20p peptide" may refer to one pep-
tide or may refer one or more peptides, such as molar con-
centrations of the peptide, as would be found in a composi-
tion. Those skilled in the art understand where an individual 
peptide is intended and where a molar, or smaller or larger 
amount, of many of the same peptide are intended. 
As used herein, the term "subject" refers to the target of 
administration, e.g., an animal. Thus, the subject of the herein 
disclosed methods can be a vertebrate, such as a manimal, a 
fish, a bird, a reptile, or an amphibian. Alternatively, the 
subject of the herein disclosed methods can be a human, Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; 
W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid. 60 non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, 
cat, guinea pig or rodent. The term does not denote a particu-
lar age or sex. Thus, adult and newborn subjects, as well as 
fetuses, whether male or female, are intended to be covered. 
"Peptide" as used herein refers to any peptide, oligopep-
tide, polypeptide, gene product, expression product, or pro-
tein. For example, a peptide can be a fragment ofa full-length 
protein, such as, for example, the CT20 Bax peptide. A pep-
tide is comprised of consecutive amino acids. The term "pep- 65 
tide" encompasses naturally occurring or synthetic mol-
ecules. 
In one aspect, the subject is a patient. A patient refers to a 
subject afflicted with a disease or disorder, such as, for 
example, cancer and/or aberrant cell growth. The term 
"patient" includes human and veterinary subjects. In some 
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aspects of the disclosed methods, the subject has been diag-
nosed with a need fortreatment for cancer and/or aberrant cell 
growth. 
-continued 
Therapeutic agents may include antimicrobial agents, such 
as antibiotics or antimycotic compounds, including but not 
limited to, active agents such as antifungal agents, antibacte-
rial agents, anti-viral agents and antiparasitic agents, and 
metals. An antimicrobial agent may comprise a substance, 
compound or molecule, that kills or inhibits the growth of 
microorganisms such as bacteria, fungi, or protozoans. Anti- 10 
microbial agents may either kill microbes (microbiocidal) or 
prevent the growth of microbes (microbiostatic). Disinfec-
tants are antimicrobial substances used on non-living objects 
or outside the body. Anitmicrobial agents include those 
obtained from natural sources, such as Beta-lactam antibiot- 15 
ics (such as penicillins, cephalosporins), and protein synthe-
sis inhibitors (such as aminoglycosides, macrolides, tetracy-
clines, chloramphenicol, polypeptides), and those from 
synthetic sources such as sulphonamides, cotrimoxazole, 
quinolones, anti-fungals, anti-cancer drugs, antimalarials, 20 
anti-tuberculosis drugs, anti-leprotics, and anti-protozoals. 
Examples of antimicrobial agents that can be used in the 
present invention include, but are not limited to, isoniazid, 
ethambutol, pyrazinamide, streptomycin, clofazimine, 
rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, 25 
rifampin, azithromycin, clarithromycin, dapsone, tetracy-
cline, erythromycin, ciprofloxacin, doxycycline, ainpicillin, 
amphotericin B, ketoconazole, fluconazole, pyrimethamine, 
sulfadiazine, clindamycin, lincomycin, pentamidine, atova-
quone, paromomycin, diclazaril, acyclovir, trifluorouridine, 30 
foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, 
miconazole, Zn-pyrithione, heavy metals including, but not 
limited to, gold, platinum, silver, zinc and copper, and their 
combined forms including, salts, such as chloride, bromide, 
iodide and periodate, and complexes with carriers, and other 35 
forms. As used herein, the term metal includes all metal salts 
or metal compounds, including, but not limited to, metal 
chlorides, metal phosphates, metal sulfates, metal iodides or 
metal bromides. The active form of some metal salts is the 
ionic form. Other antimicrobial agents include, but are not 40 
limited to, polyene antifungals, Amphotericin B, Candicidin, 
Filipin, Hamycin, Natamycin, Nystatin, Rimocidin, Imida-
zoles, Bifonazole, Butoconazole, Clotrimazole, Econazole, 
Fenticonazole, Isoconazole, Ketoconazole, Miconazole, 
Omoconazole, Oxiconazole, Sertaconazole, Sulconazole, 45 
Tioconazole, Triazoles, Albaconazole, Fluconazole, Isavu-
conazole, Itraconazole, Posaconazole, Ravuconazole, Ter-
conazole, Voriconazole, Thiazoles, Abafungin, Allylamines, 
Amorolfin, Butenafine, Naftifine, Terbinafine, Echinocan-
dins, Anidulafungin, Caspofungin, Micafungin. 50 
Examples of microbial organisms that may be treated by 
the present invention include, but are not limited to, patho-
genic fungi including, but not limited to, Candida species, 
Aspergillus species, Cryptococcus species, histoplasa spe-
cies, stachybotrus species, and pneumacystus species; bacte- 55 
ria including but not limited to: 
Calymmatobacterium granulomatis 
Campylobacter 
Campylobacter coli 60 
Bacillus 
Bacillus anthracis 
Bacillus brevis 
Bacillus cereus 
Bacillus fusiformis 
Bacillus licheniformis 
Bacillus megaterium 
Bacillus mycoides 
Bacillus stearothermophilus 
Bacillus subtilis 
Bacteroides 
Bacteroidesfragilis 
Bacteroides gingivalis 
Bacteroides melaninogenicus 
Bartonella 
Bartonella henselae 
Bartonella quintana 
Bordetella 
Bordetella bronchiseptica 
Bordetella pertussis 
Borrelia burgdorferi 
Brucella 
Brucella abortus 
Brucella melitensis 
Gardnerella vaginalis 
Klebsiella pneumoniae 
Lactobacillus 
Lactobacillus acidophilus 
Lactobacillus casei 
Lactococcus lactis 
Legionella pneumophila 
Listeria monocytogenes 
Lactobacillus Bulgaricus 
Mycoplasma 
Mycoplasmafermentans 
Mycoplasma genitalium 
Mycoplasma hominis 
Myca plasma penetrans 
Mycoplasma pneumoniae 
Methanobacterium extroquens 
Microbacterium multiforme 
Micrococcus luteus 
Moraxella catarrhalis 
Mycobacterium 
Mycobacterium avium 
Mycobacterium bovis 
Mycobacterium diphtheriae 
Mycobacterium intracellulare 
Mycobacterium leprae 
Mycobacterium lepraemurium 
Mycobacterium phlei 
Mycobacterium smegmatis 
Mycobacterium tuberculosis 
Pasteurella 
Pasteurella multocida 
Pasteurella tularensis 
Peptostreptococcus 
Porphyromonas gingivalis 
Pseudomonas aeruginosa 
Streptococcus mitior 
Streptococcus mitis 
Streptococcus mutans 
Streptococcus oralis 
Streptococcus pneumoniae 
Streptococcus pyogenes 
Streptococcus rattus 
Streptococcus salivarius 
Treponema 
Treponema pallidum 
Treponema denticola 
Vibrio 
Vibrio cholerae 
Vibrio comma 
Chlamydophila psittaci 
Clostridium 
Clostridium botulinum 
Clostridium difficile 
Clostridium perfringens 
Clostridium tetani 
Corynebacterium 
Corynebacterium diphtheriae 
Corynebacteriumfusiforme 
Coxiella bumetii 
Ehrlichia chaffeensis 
Enterobacter cloacae 
Enterococcus 
Enterococcus avium 
Enterococcus durans 
Enterococcus faecalis 
Enterococcus faecium 
Enterococcus galllinarum 
Enterococcus maloratus 
Escherichia coli 
Francisella tularensis 
Fusobacterium nucleatum 
Haemophilus 
Haemophilus ducreyi 
Haemophilus infiuenzae 
Haemophilus parainfiuenzae 
Haemophilus pertussis 
Haemophilus vaginalis 
Helicobacter pylori 
Neisseria 
Neisseria gonorrhoeae 
Neisseria meningi,tidis 
Rhizobium radiobacter 
Rickettsia 
Rickettsia prowazekii 
Rickettsia psittaci 
Rickettsia quintana 
Rickettsia rickettsii 
Rickettsia trachomae 
Rochalimaea 
Rochalimaea henselae 
Rochalimaea quintana 
Rothia dentocariosa 
Rhizobium radiobacter 
Salmonella 
Salmonella enteritidis 
Salmonella typhi 
Salmonella typhimurium 
Serratia marcescens 
Shigella dysenteriae 
Staphylococcus 
Staphylococcus aureus 
Staphylococcus epidermidis 
Stenotrophomonas maltophilia 
Streptococcus 
Streptococcus agalactiae 
Streptococcus avium 
Streptococcus bovis 
Streptococcus cricetus 
Streptococcus faceium 
Streptococcus faecalis 
Streptococcus ferus 
Streptococcus gallinarum 
Streptococcus lactis 
Streptococcus sanguis 
Streptococcus sobrinus 
Wolbachia 
Vibrio parahaemolyticus 
Vibrio vulnificus 
Yersinia 
Yersinia enterocolitica 
Yersinia pestis 
Yersinia pseudotuberculosis 
Acetobacter aurantius 
Acinetobacter baumannii 
Actinomyces israelii 
Agrobacterium radiobacter 
Agrobacterium tumefaciens 
Azorhizobium caulinodans 
Azotobacter vinelandii 
Anaplasma 
Anaplasma phagocytophilum 
Acetobacter aurantius 
Campylobacter fetus 
Campylobacter jejuni 
Campylobacter pylori 
Chlamydia 
Chlamydia trachomatis 
Chlamydophila 
Chlamydophila pneumoniae 
The terms "treating", "treatment'', "therapy", and "thera-
peutic treatment" as used herein refer to curative therapy, 
65 prophylactic therapy, or preventative therapy. As used herein, 
the terms refers to the medical management of a subject or a 
patient with the intent to cure, ameliorate, stabilize, or prevent 
US 9,040,662 B2 
23 
a disease, pathological condition, or disorder, such as, for 
example, cancer or a tumor. This term includes active treat-
ment, that is, treatment directed specifically toward the 
improvement of a disease, pathological condition, or disor-
der, disorder, and also includes causal treatment, that is, treat-
ment directed toward removal of the cause of the associated 
disease, pathological condition, or disorder. In addition, this 
term includes palliative treatment, that is, treatment designed 
for the relief of symptoms rather than the curing of the dis-
ease, pathological condition, or disorder; preventative treat-
ment, that is, treatment directed to minimizing or partially or 
completely inhibiting the development of the associated dis-
ease, pathological condition, or disorder; and supportive 
treatment, that is, treatment employed to supplement another 
specific therapy directed toward the improvement of the asso-
ciated disease, pathological condition, or disorder. In various 
aspects, the term covers any treatment of a subject, including 
a marmnal (e.g., a human), and includes: (i) preventing the 
disease from occurring in a subject that can be predisposed to 
the disease but has not yet been diagnosed as having it; (ii) 
inhibiting the disease, i.e., arresting its development; or (iii) 
relieving the disease, i.e., causing regression of the disease. In 
an aspect, the disease, pathological condition, or disorder is 
cancer, such as, for example, breast cancer, lung cancer, col-
orectal, liver cancer, or pancreatic cancer. 
As used herein, the term "prevent" or "preventing" refers to 
precluding, averting, obviating, forestalling, stopping, or hin-
dering something from happening, especially by advance 
action. It is understood that where reduce, inhibit or prevent 
are used herein, unless specifically indicated otherwise, the 
use of the other two words is also expressly disclosed. 
As used herein, the term "diagnosed" means having been 
subjected to a physical examination by a person of skill, for 
example, a physician or a researcher, and found to have a 
condition that can be diagnosed or treated by compositions or 
methods disclosed herein. For example, "diagnosed with can-
cer" means having been subjected to a physical examination 
by a person of skill, for example, a physician or a researcher, 
and found to have a condition that can be diagnosed or treated 
by a compound or composition that alleviates or ameliorates 
cancer and/or aberrant cell growth. 
As used herein, the phrase "identified to be in need of 
treatment for a disorder," or the like, refers to selection of a 
subject based upon need for treatment of the disorder. For 
example, a subject can be identified as having a need for 
treatment of a disorder (e.g., a disorder related to cancer 
and/or aberrant cell growth) based upon an earlier diagnosis 
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as intravenous administration, intraarterial administration, 
intramuscular administration, and subcutaneous administra-
tion. Administration can be continuous or intermittent. In 
various aspects, a preparation can be administered therapeu-
tically; that is, administered to treat an existing disease or 
condition. In further various aspects, a preparation can be 
administered prophylactically; that is, administered for pre-
vention of a disease or condition. 
The term "contacting" as used herein refers to bringing a 
10 disclosed composition or peptide or pharmaceutical prepara-
tion and a cell, target receptor, or other biological entity 
together in such a marmer that the compound can affect the 
activity of the target (e.g., receptor, transcription factor, cell, 
15 etc.), either directly; i.e., by interacting with the target itself, 
or indirectly; i.e., by interacting with another molecule, co-
factor, factor, or protein on which the activity of the target is 
dependent. 
As used herein, the term "determining" can refer to mea-
20 suring or ascertaining a quantity or an amount or a change in 
expression and/or activity level, e.g., of a nucleotide or tran-
script or polypeptide. For example, determining the amount 
of a disclosed transcript or polypeptide in a sample as used 
herein can refer to the steps that the skilled person would take 
25 to measure or ascertain some quantifiable value of the tran-
script or polypeptide in the sample. The art is familiar with the 
ways to measure an amount of the disclosed nucleotides, 
transcripts, polypeptides, etc. 
In an aspect, "determining" as used herein can refer to 
30 measuring or ascertaining the level of cell death or cell sur-
vival, for example, following administration of a CT20p pep-
tide or a composition comprising an effective amount of a 
CT20p peptide. Methods of measuring or ascertaining cell 
survival and cell death are known to the art and include, but 
35 are not limited to, histochemical staining (e.g., TUNEL ), cell 
proliferation assay, cell death assays, morphological exami-
nation, etc. In an aspect, the size of a tumor can be measured 
non-invasively through ultrasound. 
As used herein, the term "level" refers to the amount of a 
40 target molecule in a sample, e.g., a sample from a subject. The 
amount of the molecule can be determined by any method 
known in the art and will depend in part on the nature of the 
molecule (i.e., gene, mRNA, cDNA, protein, enzyme, etc.). 
The art is familiar with quantification methods for nucle-
45 otides (e.g., genes, cDNA, mRNA, etc) as well as proteins, 
polypeptides, enzymes, etc. It is understood that the amount 
or level of a molecule in a sample need not be determined in 
absolute terms, but can be determined in relative terms (e.g., by a person of skill and thereafter subjected to treatment for 
the disorder. It is contemplated that the identification can, in 
one aspect, be performed by a person different from the 50 
person making the diagnosis. It is also contemplated, in a 
further aspect, that the administration can be performed by 
one who subsequently performed the administration. 
when compare to a control or a sham or an untreated sample). 
As used herein, the terms "effective amount" and "amount 
effective" refer to an amount that is sufficient to achieve the 
desired result or to have an effect on an undesired condition. 
For example, in an aspect, an effective amount of a CT20p 
peptide is an amount that permeabilizes cell membranes and/ 
or kills cells without causing extraneous damage to surround-
ing non-cancerous cells. For example, a "therapeutically 
As used herein, the terms "administering" and "adminis-
tration" refer to any method of providing a peptide (such as a 55 
CT20 Bax peptide), or a composition (such as a composition 
comprising a CT20 Bax peptide), or pharmaceutical prepa-
ration (such as a preparation comprising a CT20p peptide or 
a composition comprising a CT20 Bax peptide) to a subject. 
Such methods are well known to those skilled in the art and 60 
effective amount" refers to an amount that is sufficient to 
achieve the desired therapeutic result or to have an effect on 
undesired symptoms, but is generally insufficient to cause 
adverse side affects. The specific therapeutically effective 
dose level for any particular patient will depend upon a vari-
ety of factors including the disorder being treated and the 
severity of the disorder; the specific composition employed; 
the age, body weight, general health, sex and diet of the 
include, but are not limited to, intracardiac administration, 
oral administration, transdermal administration, administra-
tion by inhalation, nasal administration, topical administra-
tion, intravaginal administration, ophthalmic administration, 
intraaural administration, intracerebral administration, rectal 
administration, sublingual administration, buccal administra-
tion, and parenteral administration, including injectable such 
65 patient; the time of administration; the route of administra-
tion; the rate of excretion of the specific compound employed; 
the duration of the treatment; drugs used in combination or 
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coincidental with the specific compound employed and like 
factors well known in the medical arts. 
By "modulate" is meant to alter, by increase or decrease. 
As used herein, a "modulator" can mean a composition that 
can either increase or decrease the expression level or activity 
level of a gene or gene product such as a peptide. Modulation 
in expression or activity does not have to be complete. For 
example, expression or activity can be modulated by about 
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 
99%, 100% or any percentage in between as compared to a 
control cell wherein the expression or activity of a gene or 
gene product has not been modulated by a composition. 
As used herein, "EC50,'' is intended to refer to the concen-
tration or dose of a substance (e.g., a CT20p peptide or a 
disclosed composition comprising a CT20p peptide) that is 
required for 50% enhancement or activation of a biological 
process, or component of a process, including a protein, sub-
unit, organelle, ribonucleoprotein, etc. EC50 also refers to the 
concentration or dose of a substance that is required for 50% 
enhancement or activation in vivo, as further defined else-
where herein. Alternatively, EC50 can refer to the concentra-
tion or dose of compound that provokes a response hal:!Way 
between the baseline and maximum response. The response 
can be measured in an in vitro or in vivo system as is conve-
nient and appropriate for the biological response of interest. 
For example, the response can be measured in vitro using 
cultured cancer cells or in an ex vivo organ culture system 
with isolated cancer cells, e.g., pancreatic cancer cells, breast 
cancer cells, liver cancer cells, lung cancer cells, colorectal 
cancer cells, etc.). Alternatively, the response can be mea-
sured in vivo using an appropriate research model such as 
rodent, including mice and rats. The mouse or rat can be an 
inbred strain with phenotypic characteristics of interest such 
as, for example, cancer and/or aberrant cell growth. As appro-
priate, the response can be measured in a transgenic or knock-
out mouse or rat wherein a gene or genes has been introduced 
or knocked-out, as appropriate, to replicate a disease process. 
As used herein, "IC50,'' is intended to refer to the concen-
tration or dose of a substance (e.g., a CT20p peptide or a 
disclosed composition comprising a CT20p peptide) that is 
required for 50% inhibition or diminution of a biological 
process, or component of a process, including a protein, sub-
unit, organelle, ribonucleoprotein, etc. IC50 also refers to the 
concentration or dose of a substance that is required for 50% 
inhibition or diminution in vivo, as further defined elsewhere 
herein. Alternatively, IC50 also refers to the half maximal 
(50%) inhibitory concentration (IC) or inhibitory dose of a 
substance. The response can be measured in an in vitro or in 
vivo system as is convenient and appropriate for the biologi-
cal response of interest. For example, the response can be 
measured in vitro using cultured cancer cells or in an ex vivo 
organ culture system with isolated cancer cells (e.g., breast 
cancer cells, pancreatic cancer cells, liver cancer cells, lung 
cancer cells, colorectal cancer cells, etc.). Alternatively, the 
response can be measured in vivo using an appropriate 
research model such as rodent, including mice and rats. The 
mouse or rat can be an inbred strain with phenotypic charac-
teristics of interest such as, for example, cancer and/or aber-
rant cell growth. As appropriate, the response can be mea-
sured in a transgenic or knockout mouse or rat wherein a gene 
or genes has been introduced or knocked-out, as appropriate, 
to replicate a disease process. 
The term "pharmaceutically acceptable" describes a mate-
rial that is not biologically or otherwise undesirable, i.e., 
without causing an unacceptable level of undesirable biologi-
cal effects or interacting in a deleterious manner. As used 
herein, the term "pharmaceutically acceptable carrier" refers 
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to sterile aqueous or nonaqueous solutions, dispersions, sus-
pensions or emulsions, as well as sterile powders for recon-
stitution into sterile injectable solutions or dispersions just 
prior to use. Examples of suitable aqueous and nonaqueous 
carriers, diluents, solvents or vehicles include water, ethanol, 
polyols (such as glycerol, propylene glycol, polyethylene 
glycol and the like), carboxymethylcellulose and suitable 
mixtures thereof, vegetable oils (such as olive oil) and inject-
able organic esters such as ethyl oleate. Proper fluidity can be 
10 maintained, for example, by the use of coating materials such 
as lecithin, by the maintenance of the required particle size in 
the case of dispersions and by the use of surfactants. These 
compositions can also contain adjuvants such as preserva-
tives, wetting agents, emulsifying agents and dispersing 
15 agents. Prevention of the action of microorganisms can be 
ensured by the inclusion of various antibacterial and antifun-
gal agents such as paraben, chlorobutanol, phenol, sorbic acid 
and the like. It can also be desirable to include isotonic agents 
such as sugars, sodium chloride and the like. Prolonged 
20 absorption of the injectable pharmaceutical form can be 
brought about by the inclusion of agents, such as aluminum 
monostearate and gelatin, which delay absorption. Injectable 
depot forms are made by forming microencapsule matrices of 
the drug in biodegradable polymers such as polylactide-
25 polyglycolide, poly(orthoesters) and poly(anhydrides). 
Depending upon the ratio of drug to polymer and the nature of 
the particular polymer employed, the rate of drug release can 
be controlled. Depot injectable formulations are also pre-
pared by entrapping the drug in liposomes or microemulsions 
30 which are compatible with body tissues. The injectable for-
mulations can be sterilized, for example, by filtration through 
a bacterial-retaining filter or by incorporating sterilizing 
agents in the form of sterile solid compositions which can be 
dissolved or dispersed in sterile water or other sterile inject-
35 able media just prior to use. Suitable inert carriers can include 
sugars such as lactose. Desirably, at least 95% by weight of 
the particles of the active ingredient have an effective particle 
size in the range of0.01to10 micrometers. 
As used herein, the term "cancer" refers to a proliferative 
40 disorder or disease caused or characterized by the prolifera-
tion of cells which have lost susceptibility to normal growth 
control. The term "cancer" includes tumors and any other 
proliferative disorders. Cancers of the same tissue type origi-
nate in the same tissue, and may be divided into different 
45 subtypes based on their biological characteristics. Cancer 
includes, but is not limited to, melanoma, leukemia, astocy-
toma, glioblastoma, lymphoma, glioma, Hodgkins lym-
phoma, and chronic lymphocyte leukemia. Cancer also 
includes, but is not limited to, cancer of the brain, bone, 
50 pancreas, lung, liver, breast, thyroid, ovary, uterus, testis, 
pituitary, kidney, stomach, esophagus, anus, and rectum. 
As used herein, the term "sensitizing" refers to an 
increased sensitivity of a cell or a subject to a treatment, such 
as a therapeutic treatment. The term "sensitizing" also refers 
55 to a reduction or decrease in the resistance of a cancer cell or 
a subject with cancer in responding to a therapeutic treatment. 
An increased sensitivity or a reduced sensitivity to a thera-
peutic treatment is measured according to a known method in 
the art for the particular treatment and methods including, but 
60 not limited to, cell proliferation assays and cell death assays. 
The sensitivity or resistance may also be measured in a sub-
ject by measuring the tumor size reduction over a period of 
time, such as, for example, every 1 to 3 to 6 month for a human 
subject and every 2 to 4 to 6 weeks for non-human subject 
65 (e.g., mouse or rat). The sensitivity of a cell or a subject to 
treatment can be measured or determined by comparing the 
sensitivity of a cell or a subject following administration of a 
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CT20p peptide or a composition comprising an effective 
amount of a CT20p peptide to the sensitivity of a cell or 
subject that has not been administered a CT20p peptide or a 
composition comprising an effective amount of a CT20p 
peptide. 
As used herein, the term "anti-cancer" or "anti-neoplastic" 
drug refers to one or more drugs that can be used in conjunc-
tion with a CT20p peptide or a composition comprising an 
effective amount of a CT20p peptide to treat cancer and/or 
aberrant cell growth. Examples of anti-cancer drugs or anti- 10 
neoplastic drugs include, but are not limited to, the following: 
Acivicin; Aclarubicin; Acodazole Hydrochloride; AcrQnine; 
Adozelesin; Aldesleukin; Altretamine; Ambomycin; Amet-
antrone Acetate; Aminoglutethimide; Amsacrine; Anastro-
zole; Anthramycin; Asparaginase; Asperlin; Azacitidine; 15 
Azetepa; Azotomycin; Batimastat; Benzodepa; Bicaluta-
mide; Bisantrene Hydrochloride; Bisnafide Dimesylate; 
Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropir-
imine; Busulfan; Cactinomycin; Calusterone; Caracemide; 
Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochlo- 20 
ride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; 
Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophospha-
mide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubi-
cin Hydrochloride; Decitabine; Dexormaplatin; Dezagua-
nine; Dezaguanine Mesylate; Diaziquone; Docetaxel; 25 
Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; 
Droloxifene Citrate; Dromostanolone Propionate; Duazomy-
cin; Edatrexate; Eflomithine Hydrochloride; Elsamitrucin; 
Enloplatin; Enpromate; Epipropidine; Epirubicin Hydro-
chloride; Erbulozole; Esorubicin Hydrochloride; Estramus- 30 
tine; Estramustine Phosphate Sodium; Etanidazole; 
Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Eto-
prine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; 
Floxuridine; Fludarabine Phosphate; Fluorouracil; Fluoroc-
itabine; Fosquidone; Fostriecin Sodium; Gemcitabine; Gem- 35 
citabine Hydrochloride; Gold Au 198; Hydroxyurea; Idaru-
bicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon 
Alfa-2a; Interferon Alfa-2b; Interferon Alfa-nl; Interferon 
Alfa-n3; Interferon Beta-la; Interferon Ganima 1 b; Ipropl-
atin; Irinotecan Hydrochloride; Lanreotide Acetate; Letro- 40 
zole; Leuprolide Acetate; Liarozole Hydrochloride; Lometr-
exol Sodium; Lomustine; Losoxantrone Hydrochloride; 
Masoprocol; Maytansine; Mechlorethamine Hydrochloride; 
Megestrol Acetate; Melengestrol Acetate; Melphalan; 
Menogaril; Mercaptopurine; Methotrexate; Methotrexate 45 
Sodium; Metoprine; Meturedepa; Mitindomide; Mitocarcin; 
Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; 
Mitotane; Mitoxantrone Hydrochloride; MycophenolicAcid; 
Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Pacli-
taxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin 50 
Sulfate; Perfosfamide; Pipobroman; Piposulfan; Pirox-
antrone Hydrochloride; Plicamycin; Plomestane; Porfimer 
Sodium; Porfiromycin; Prednimustine; Procarbazine Hydro-
chloride; Puromycin; Puromycin Hydrochloride; Pyrazofu-
rin; Riboprine; Rogletimide; Safingol; Safingol Hydrochlo- 55 
ride; Semustine; Simtrazene; Sparfosate Sodium; 
Sparsomycin; Spirogermanium Hydrochloride; Spiromus-
tine; Spiroplatin; Streptonigrin; Streptozocin; Strontium 
Chloride Sr 89; Sulofenur; Talisomycin; Taxane; Taxoid; Tec-
ogalan Sodium; Tegafur; Teloxantrone Hydrochloride; 60 
Temoporfin; Teniposide; Teroxirone; Testolactone; Thiami-
prine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; 
Topotecan Hydrochloride; Toremifene Citrate; Trestolone 
Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate 
Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil 65 
Mustard; Uredepa; Vapreotide; Verteporfin; Vinblastine Sul-
fate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vine-
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pidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; 
Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sul-
fate; Vorozole; Zeniplatin; Zinostatin; Zorubicin Hydrochlo-
ride. 
Other anti-neoplastic compounds include: 20-epi-1,25 
dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubi-
cin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-
TK antagonists; altretamine; ambamustine; amidox; amifos-
tine; aminolevulinic acid; anrrubicin; atrsacrine; anagrelide; 
anastrozole; andrographolide; angiogenesis inhibitors; 
antagonist D; antagonist G; antarelix; anti-dorsalizing mor-
phogenetic protein-I; antiandrogen, antiandrogen, pro static 
carcinoma; antiestrogen; antineoplaston; antisense oligo-
nucleotides; aphidicolin glycinate; apoptosis gene modula-
tors; apoptosis regulators; apurinic acid; ara-CDP-DL-
PTBA; argmme deaminase; asulacrine; atamestane; 
atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; aza-
setron; azatoxin; azatyrosine; baccatin III derivatives; bal-
anol; batimastat; BCR/ ABL antagonists; benzochlorins; ben-
zoylstaurosporine; beta lactam derivatives; beta-alethine; 
betaclamycin B; betulinic acid; bFGF inhibitor; bicaluta-
mide; bisantrene; bisaziridinylspermine; bisnafide; bistratene 
A; bizelesin; breflate; bropirimine; budotitane; buthionine 
sulfoximine; calcipotriol; calphostin C; camptothecin deriva-
tives; canarypox IL-2; capecitabine; carboxamide-amino-
triazole; carboxyamidotriazole; CaRest M3; CARN 700; car-
tilage derived inhibitor; carzelesin; casein kinase inhibitors 
(ICOS); castanospermine; cecropin B; cetrorelix; chlorins; 
chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; 
cladribine; clomifene analogues; clotrimazole; collismycin 
A; collismycin B; combretastatin A4; combretastatin ana-
logue; conagenin; crambescidin 816; crisnatol; cryptophycin 
8; cryptophycin A derivatives; curacin A; cyclopentan-
thraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; 
cytolytic factor; cytostatin; dacliximab; decitabine; dehy-
drodidenmin B; deslorelin; dexifosfamide; dexrazoxane; 
dexverapamil; diaziquone; didenmin B; didox; diethylnor-
spermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamy-
cin; diphenyl spiromustine; docosanol; dolasetron; doxifluri-
dine; droloxifene; dronabinol; duocannycin SA; ebselen; 
ecomustine; edelfosine; edrecolomab; eflornithine; elemene; 
emitefur; epirubicin; epristeride; estramustine analogue; 
estrogen agonists; estrogen antagonists; etanidazole; etopo-
side phosphate; exemestane; fadrozole; fazarabine; fenretin-
ide; filgrastim; finasteride; flavopiridol; flezelastine; fluaster-
one; fludarabine; fluorodaunorunicin hydrochloride; 
forfenimex; formestane; fostriecin; fotemustine; gadolinium 
texaphyrin; gallium nitrate; galocitabine; ganirelix; gelati-
nase inhibitors; gemcitabine; glutathione inhibitors; hepsul-
fam; heregulin; hexamethylene bisacetamide; hypericin; 
ibandronic acid; idarubicin; idoxifene; idramantone; ilmo-
fosine; ilomastat; imidazoacridones; imiquimod; immuno-
stimulant peptides; insulin-like growth factor-I receptor 
inhibitor; interferon agonists; interferons; interleukins; 
iobenguane; iododoxorubicin; 4-ipomeanol; irinotecan; 
iroplact; irsogladine; isobengazole; isohomohalicondrin B; 
itasetron; jasplakinolide; kahalalide F; lamellarin-N triac-
etate; lanreotide; leinamycin; lenograstim; lentinan sulfate; 
leptolstatin; letrozole; leukemia inhibiting factor; leukocyte 
alpha interferon; leuprolide+estrogen+progesterone; leupro-
relin; levamisole; liarozole; linear polyamine analogue; lipo-
philic disaccharide peptide; lipophilic platinum compounds; 
lissoclinamide 7; lobaplatin; lombricine; lometrexol; 
lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; 
lutetium texaphyrin; lysofylline; lytic peptides; maitansine; 
mannostatin A; marimastat; masoprocol; maspin; matrilysin 
inhibitors; matrix metalloproteinase inhibitors; menogaril; 
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merbarone; meterelin; methioninase; metoclopramide; MIF 
inhibitor; mifepristone; miltefosine; mirimostim; mis-
matched double stranded RNA; mitoguazone; mitolactol; 
mitomycin analogues; mitonafide; mitotoxin fibroblast 
growth factor-saporin; mitoxantrone; mofarotene; molgra-
mostim; monoclonal antibody, human chorionic gonadotro-
phin; monophosphoryl lipid A+myobacterium cell wall sk; 
mopidamol; multiple drug resistance genie inhibitor; mul-
tiple tumor suppressor I-based therapy; mustard anticancer 
agent; mycaperoxide B; mycobacterial cell wall extract; 10 
myriaporone; N-acetyldinaline; N-substituted benzamides; 
nafarelin; nagrestip; naloxone+pentazocine; napavin; naph-
terpin; nartograstim; nedaplatin; nemorubicin; neridronic 
acid; neutral endopeptidase; nilutamide; nisamycin; nitric 
oxide modulators; nitroxide antioxidant; nitrullyn; 06-ben- 15 
zylguanine; octreotide; okicenone; oligonucleotides; 
onapristone; ondansetron; oracin; oral cytokine inducer; 
ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel 
analogues; paclitaxel derivatives; palauamine; palmitoyl-
rhizoxin; pamidronic acid; panaxytriol; panomifene; para- 20 
bactin; pazelliptine; pegaspargase; peldesine; pentosan 
polysulfate sodium; pentostatin; pentrozole; perflubron; per-
fosfamide; perillyl alcohol; phenazinomycin; phenylacetate; 
phosphatase inhibitors; picibanil; pilocarpine hydrochloride; 
pirarubicin; piritrexim; placetin A; placetin B; plasminogen 25 
activator inhibitor; platinum complex; platinum compounds; 
platinum-triamine complex; porfimer sodium; porfiromycin; 
propyl bis-acridone; prostaglandin 12; proteasome inhibitors; 
protein A-based immune modulator; protein kinase C inhibi-
tors; microalgal; protein tyrosine phosphatase inhibitors; 30 
purine nucleoside phosphorylase inhibitors; purpurins; pyra-
zoloacridine; pyridoxylated hemoglobin polyoxyethylene 
conjugate; rafantagonists; raltitrexed; ramosetron; ras farne-
30 
ity of cancer cells and/or a tumor to iomzmg radiation, 
thereby increasing the efficacy of radiotherapy. Examples of 
radiosensitizers include gemcitabine, 5-fluorouracil, pentoxi-
fylline, and vinorelbine. 
The majority of chemotherapeutic drugs can be divided in 
to: alkylating agents (e.g., cisplatin, carboplatin, oxaliplatin, 
mechloethamine, cyclophosphamide, chlorambucil, anti-me-
tabolites (e.g., azathioprine, mercaptopurine ), anthracy-
clines, plant alkaloids and terpenoids (e.g., vinca alkaloids 
(e.g., vincristine, vinblastine, vinorelbine, vindesine, and 
podophyllotoxin) and taxanes (e.g., paclitaxel and doc-
etaxel ), topoisomerase inhibitors (e.g., irinotecan, topotecan, 
amsacrine, etoposide, etoposide phosphate, and teniposide ), 
monoclonal antibodies (e.g., trastuzumab, cetuximab, ritux-
imab, bevacizumab ), other antitumour agents (e.g., dactino-
mycin), and hormonal therapy (e.g., steroids such as dexam-
ethasone ), finasteride, aromatase inhibitors, and 
gonadotropin-releasing hormone agonists). 
Disclosed are the components to be used to prepare a 
composition of the invention as well as the compositions 
themselves to be used within the methods disclosed herein. 
These and other materials are disclosed herein, and it is under-
stood that when combinations, subsets, interactions, groups, 
etc. of these materials are disclosed that while specific refer-
ence of each various individual and collective combinations 
and permutation of these compounds can not be explicitly 
disclosed, each is specifically contemplated and described 
herein. For example, if a particular compound is disclosed 
and discussed and a number of modifications that can be made 
to a number of molecules including the compounds are dis-
cussed, specifically contemplated is each and every combi-
nation and permutation of the compound and the modifica-
tions that are possible unless specifically indicated to the 
contrary. Thus, if a class of molecules A, B, and C are dis-
closed as well as a class of molecules D, E, and F and an 
example of a combination molecule, A-D is disclosed, then 
even if each is not individually recited each is individually 
and collectively contemplated meaning combinations, A-E, 
A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered dis-
closed. Likewise, any subset or combination of these is also 
disclosed. Thus, for example, the sub-group of A-E, B-F, and 
C-E would be considered disclosed. This concept applies to 
all aspects of this application including, but not limited to, 
steps in methods of making and using the compositions of the 
invention. Thus, if there are a variety of additional steps that 
can be performed it is understood that each of these additional 
steps can be performed with any specific embodiment or 
combination of embodiments of the methods of the invention. 
All patents, patent applications, and other scientific or 
technical writings referred to anywhere herein are incorpo-
rated by reference in their entirety. The invention illustra-
tively described herein suitably can be practiced in the 
absence of any element or elements, limitation or limitations 
that are not specifically disclosed herein. Thus, for example, 
in each instance herein any of the terms "comprising", "con-
sisting essentially of, and "consisting of can be replaced with 
either of the other two terms, while retaining their ordinary 
meanings. The terms and expressions which have been 
employed are used as terms of description and not oflimita-
tion, and there is no intention that in the use of such terms and 
expressions of excluding any equivalents of the features 
shown and described or portions thereof, but it is recognized 
that various modifications are possible within the scope of the 
invention claimed. Thus, it should be understood that 
syl protein transferase inhibitors; ras inhibitors; ras-GAP 
inhibitor; retelliptine demethylated; rhenium Re 186 etidr- 35 
onate; rhizoxin; ribozymes; RII retinamide; rogletimide; 
rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; 
safingol; saintopin; SarCNU; sarcophytol A; sargramostim; 
Sdi 1 mimetics; semustine; senescence derived inhibitor 1; 
sense oligonucleotides; signal transduction inhibitors; signal 40 
transduction modulators; single chain antigen binding pro-
tein; sizofuran; sobuzoxane; sodium borocaptate; sodium 
phenylacetate; solverol; somatomedin binding protein; son-
ermin; sparfosic acid; spicamycin D; spiromustine; spleno-
pentin; spongistatin 1; squalamine; stem cell inhibitor; stem- 45 
cell division inhibitors; stipiamide; stromelysin inhibitors; 
sulfmosine; superactive vasoactive intestinal peptide antago-
nist; suradista; suramin; swainsonine; synthetic glycosami-
noglycans; tallimustine; tamoxifen methiodide; tauromus-
tine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; 50 
telomerase inhibitors; temoporfin; temozolomide; tenipo-
side; tetrachlorodecaoxide; tetrazomine; thaliblastine; thali-
domide; thiocoraline; thrombopoietin; thrombopoietin 
mimetic; thymalfasin; thymopoietin receptor agonist; thy-
motrinan; thyroid stimulating hormone; tin ethyl etiopurpu- 55 
rin; tirapazamine; titanocene dichloride; topotecan; topsen-
tin; toremifene; totipotent stem cell factor; translation 
inhibitors; tretinoin; triacetyluridine; triciribine; trimetrex-
ate; triptorelin; tropisetron; turosteride; tyrosine kinase 
inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogeni- 60 
ta! sinus-derived growth inhibitory factor; urokinase receptor 
antagonists; vapreotide; variolin B; vector system, erythro-
cyte gene therapy; velaresol; veramine; verdins; verteporfin; 
vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeni-
platin; zilascorb; zinostatin stimalamer. 65 although the present invention has been specifically disclosed 
by embodiments, optional features, modification and varia-
tion of the concepts herein disclosed can be resorted to by 
As used herein, radiosensitizers make a cancer cell more 
likely to be damaged. Radiosensitizers enhance the sensitiv-
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those skilled in the art, and that such modifications and varia-
tions are considered to be within the scope of this invention as 
defined by the description and the appended claims. 
32 
haker et al., 2011 ). The Protea Tuner IRES2 system 
(Clontech) also had the marker protein GFP downstream to 
the internal ribosome entry sequence (IRES) and was trans-
lated independently of the DD-tagged protein. Cells were 
0004. Experimental 
The following examples are put forth so as to provide those 
5 transiently transfected using the TransIT-LTl transfection 
reagent (Minis) for 24 hours and microscopically assayed for 
GFP expression. Expression of DD-tagged proteins was 
induced for 4-5 hours by adding 500 nM of Shield (Clontech). of ordinary skill in the art with a complete disclosure and 
description of how the compounds, compositions, articles, 
devices and/or methods claimed herein are made and evalu-
ated, and are intended to be purely exemplary of the invention 
and are not intended to limit the scope of what the inventors 
regard as their invention. However, those of skill in the art 
should, in light of the present disclosure, appreciate that many 
changes can be made in the specific embodiments which are 15 
disclosed and still obtain a like or similar result without 
MDA-MB-231 cells were transiently transfected with 
10 pcDNA-Bcl2 (or as control pEGFP (Clontech)) using the 
TransIT-LTl transfectionreagent (Minis). To assess transfec-
tion efficiency, cells were assayed microscopically for EGFP 
expression. To assess Bcl-2 expression, cells lysates were 
immunoblotted. 
departing from the spirit and scope of the invention. 
d. Detection of Mitochondrial Translocation 
Mitochondrial and cytosolic proteins were isolated using a 
mitochondrial enrichment kit (Pierce). Western blots were 
run using 12-15% SDS-PAGE gels and PVDF membranes 
and probed with the following primary antibodies: 16Bl2 
Efforts have been made to ensure accuracy with respect to 
numbers (e.g., amounts, temperature, etc.), but some errors 
and deviations should be accounted for. Unless indicated 
otherwise, parts are parts by weight, temperature is in ° C. or 
is at ambient temperature, and pressure is at or near atmo-
spheric. 
1. General Experiments 
20 anti-HA mouse monoclonal (Covance) for HA-tagged Bax; 
631073Anti-DD monoclonal (Clontech) for DD-Bax; N-20 
(Santa Cruz) for endogenous Bax; Ab-2 (Fitzgerald) for pro-
hibitin; C20 (MAPK) (Santa Cruz) for p38 MAP kinase; and 
rabbit polyclonal for Bcl-2 (Santa Cruz). The appropriate 
a. Establishment of Cell Lines 25 secondary antibodies conjugated to horseradish peroxidase 
(HRP) was then used and visualized with enhanced chemilu-
minescence kit (Pierce). Molecular weight markers (SeeB!ue 
Plus 2 (Invitrogen)) were used to approximate the position of 
The Flp-In T-REx-293 cell line (Invitrogen) stably 
expressed the lacZ-Zeocin fusion gene and Tet repressor. The 
293 line was maintained in Dulbecco's Modified Eagle 
Medium (DMEM), 10% fetal bovine serum (FBS) (tetracy-
cline-reduced), 2 mM L-glutamine and 1 % Penicillin-Strep- 30 
tomycin. The HCT-116 Bax_;_ and Bax+/+ colorectal cancer 
cell lines (Zhang et al., 2000) were maintained in McCoy's 
SA media, 10% FBS, and 1 % Penicillin-Streptomycin. The 
breast cancer cell lines, MCF-7 and MCB-MD-231 (ATCC), 
were maintained in DMEM, 10% FBS, and 1 % Penicillin- 35 
Streptomycin. MCF-7 cells were supplemented with 1 % 
L-Glutamine every 15 days. Early passages of all cell lines 
were frozen as stocks at time of receipt. Cell lines were used 
at less than 10 passages from stocks. 
protein bands in blots. 
e. Co-Localization of Mitochondrial Proteins 
To determine whether expression of DD-tagged Bax C-ter-
minal peptides co-localized with mitochondria, Bax+/+ HCT-
116 cells and Bax-1- HCT-116 cells were cultured for 24 
hours on coverslips pretreated with laminin. The DD-Bax 
C-terminal WT peptide and DD-Bax C-terminal EE, LL, and 
RR mutations constructs were transfected into the cells using 
Minis LT-1 reagent according manufacturer's protocol. After 
24 hours, expression of the transfected peptides was induced 
by the addition of shield 1 for 4 hrs. Cells were fixed with 2% 
b. Generation of the CT20 Bax Peptide 
The CT20p peptide (Ac-VITFVAGVLTASLTIWKKMG-
NH2) (Biopeptide Co., Inc.) (SEQ ID NO: 53) was commer-
cially synthesized at >98% purity. 
C. Generation of Plasmids for Muta genesis and Transfec-
tion 
40 w/v formaldehyde/PBS for 15 minutes and permeabilized 
using 0.05% Triton X-100/PBS for 15 minutes. After wash-
ing, cells were incubated with primary antibodies HSP60 
(H-300, Santa Cruz) and DD monoclonal antibody for 1 hour 
at room temperature, which was followed by incubation with 
45 secondary anti-rabbit-Cy3 (81-6115, Invitrogen) and anti-
mouse-Texas red (715076020, Jackson Immunoresearch) for 
30 minutes. After the final wash, cells were mounted with 
gel/mount medium (Mo!, Biomeda) and images were 
For inducible expression of Bax, the Flp-In T-REx System 
(Invitrogen) was utilized according to the manufacturer's 
protocol. Briefly, PCR-directed mutagenesis of Kl 89/Kl 90 
was performed using HA-tagged primer sets (Table 1). Bax 
constructs were amplified from pEGFP-Bax, digested with 50 
EcoRV, and cloned into the plasmid pcDNA5/FRT /TO, which 
undergoes DNA recombination at the Flp Recombination 
Target (FRT) site when co-expressed with the Flp recombi-
nase pOG44 plasmid. Constructs were confirmed by 
sequencing. Fu gene transfection reagent (Roche) was used to 55 
co-transfect plasmids at a ratio of 9:1. Stable Flp-In T-REx 
expression cell lines were selected for Blasticidin resistance 
(10 µg/mL ), Hygromycin resistance (100 µg/mL) and Zeocin 
sensitivity (200 µg/mL). Bax expression was induced with 1 
µg/mL tetracycline. Cells were assayed after 24 hours of 60 
induction. See Table 1 for sequences and primers used herein. 
To generate the Destabilization Domain (DD)-tagged Bax 
CT (amino acids 173-192) fusion proteins with Kl89/Kl90 
(wild-type) or EE, LL, and RR mutations, primers (Table 1) 
were annealed and ligated into the Protea Tuner vector (Clan- 65 
tech) digested by EcoRI and BamHI. Generation of DD-
tagged, full-length WT Bax was previously described (Boo-
acquired with Ultra View (PerkinElmer) microscopy with a 
plan-apochromat 63x/l .4 oil objective. The scanned images 
were processed and Pearson's correlation coefficients deter-
mined using Velocity Version 5.5 (Perkin Elmer). 
f. Generation and Expression of EGFP-CT20p Peptide 
Fusion Constructs 
To generate the EGFP-CT20p peptide fusion proteins, 
primers incorporating the CT (amino acids 173-192) of Bax 
with mutations targeting Kl 89/Kl 90 (Table 1) were used to 
amplify EGFP from the template pEGFP (Clontech). The 
PCR insert was cloned into pcDNA5/FRT/TO as previously 
above. HCT-116 cells were transiently transfected using the 
TransIT-LTl transfection reagent (Minis) and cells assayed 
microscopically for EGFP expression up to 12 hours later. 
g. Confocal Imaging of Live Cells 
Images were acquired through a PerkinElmer Ultra View 
spinning disc confocal system with AxioObserver.Zl stand 
(Carl Zeiss) in a humidity and temperature-controlled cham-
ber (LiveCell) with cells cultured on MatTek plates (MatTek 
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Corporation). Post-acquisition snapshots were taken from 
time-lapse movies at time points indicated in the figures. For 
EGFP-CT20 Bax fusion proteins, time-lapse movies were 
initiated two hours after transfection and images acquired 
through 12 hours of expression using a Plan-Apochromat 1 Ox 5 
objective. For DD-CT20 Bax fusion proteins, cells were incu-
bated with 1 nM MitoTracker Red 580 for 30 minutes prior to 
imaging. Time-lapse movies were recorded for up to 12 hours 
using a Plan-Apochromat 63x Oil DIC objective. 
Visualization of the uptake and effects of the fluorescent 10 
dye (DiI)-loaded nanoparticles in HCT-116, MCF-7, and 
MDA-MD-231 cells was observed using a !Ox air objective 
with a numerical aperture of0.3, using ex/em of 514/587. All 
cells were loaded with MitoTracker. Visualization of the 
HCT-116 cell lines was observed using Plan-Apochromat 15 
63x Oil objective. MCF-7 and MDA-MB-231 images were 
captured using Plan-Apochromat 40x Oil objective. All time-
lapse images were generated in 2D by capturing 6 time points 
per hour for 24 hours of the same field. 
h. Treatments and Detection of Apoptotic Cells by Flow 20 
Cytometry 
HCT-116, MCF-7, or MDA-MB-231 cells were collected 
at a final concentration of 1x106 cells/mL and assayed using 
the SYTOX® AADvanced™ dead cell stain solution (Invit-
rogen). Cells were analyzed using the BD FACSCanto flow 25 
cytometer. SYTOX® AADvanced™ was visualized at 488 
nm and emissions collected at 695 nm. Analysis of data was 
done using FSC Express software (DeNovo). Membrane 
asymmetry was assessed using the Violet Ratiometric Mem-
brane Asymmetry Probe/Dead Cell Apoptosis Kit (Invitro- 30 
gen) according to the manufacturer's protocol. 
To evaluate apoptosis, cells were pre-treated with 100 µM 
of the pan-caspase inhibitor Z-VAD-fmk (EMD Biosciences) 
or transiently transfected with Bcl-2, then treated with either 
CT20/nanoparticles or cisplatin (CDDP) alone or in combi- 35 
nation as indicated in figure legends. Following treatment, 
cells were analyzed for cell death and membrane asymmetry. 
i. Synthesis of Polymeric Nanoparticles Encapsulating the 
Bax CT20 Bax Peptide 
The Bax CT20p peptide was encapsulated into hyper- 40 
branched polymeric (HBPE) nanoparticles following a pre-
viously reported method (Santra et al., 2010). A fluorescent 
dye (DiI) was co-encapsulated with the peptide. In brief, 1.0 
µL, ofDiI dye (10 µg/µL) and36 µL, ofCT20p peptide (0.05 
µg/µL) solution in 250 µL, ofDMSO were mixed in 250 µL of 45 
a DMSO solution containing the HBPE polymer (12 mg) for 
a ratio of -0.15 µg peptide: 1 mg nanoparticles. The resulting 
polymer-Dil/Bax mixture in DMSO was added to deionized 
water (2.5 mL) to form the HBPE (Bax CT20/DiI) nanopar-
ticles. The resulting nanoparticles were purified using a 50 
PD-10 column and dialyzed (MWCO 6-8K) against PBS 
(pH=7.4). Dynamic light scattering and zeta potential analy-
sis of the nanoparticle reveals a size diameter of 88±2 nm and 
zeta potential of -54.5 mV. 
j. Synthesis of Aminated Polymeric Nanoparticles Encap- 55 
sulating the CT20 Bax Peptide 
The HBPE nanoparticles contain functional carboxylic 
groups on their surface that resulted in a negative charge. To 
introduce a positively charged surface, the nanoparticles were 
aminated using water-soluble carbodiimide chemistry [EDC: 60 
1-ethy 1-3-(3-dimethy lamino-propy l)carbodiimide hydro-
chloride and NHS: N-hydroxysuccinimide chemistry], fol-
lowing a previously reported method (Santra et al., 2010). 
Briefly, to a solution ofHBPE (Bax CT20/DiI) nanoparticles 
(1.0 mmol) in PBS (pH=7.4), a solution ofEDC (10 mmol) 65 
and NHS (10 mmol) in MES buffer (pH=6.0) was added. 
Afterwards, ethylenediamine (10 mmol) in DMSO was added 
34 
to obtain aminated DiI/Bax co-encapsulation polymeric 
nanoparticles (PNPs ), which were purified and dialyzed. 
Dynamic light scattering and zeta potential analysis of the 
nanoparticle reveals a nanoparticle size diameter or 91 ±3 nm 
and zeta potential of+ 10.3 m V. All nanoparticles were stored 
at 4° C. A final working concentration of350 pM was deter-
mined by testing the toxicity of 7 nM, 1.4 nM, 0.7 nM, and 
0.35 nM using HCT-116+1+ cells. 
k. Determination of Calcein Release 
Calcein release from artificial membranes was measured 
on a JASCO 810 spectropolarimeter (Jasco Inc.) with a Peltier 
water cooled thermostat and a photomultiplier tube mounted 
at 90 degrees for fluorescence measurements. Large unila-
mellar vesicles (LUVs) were prepared with the following 
modifications: Lipids (Avanti Polar Lipids) in chloroform 
were mixed in the following molar ratios: 52.5% l-palmitoyl-
2-oleyl-sn-glycero-3-phosphatidylcholine (POPC), 21 % 
1-palmitoy 1-2-oley l-sn-glycero-3-phosphatidy lethanola-
mine (POPE), 13% bovine liver L-a phosphatidylinositol 
(PI), 10% cholesterol and 3.5% l-palmitoyl-2-oleyl-sn-glyc-
ero-3-phosphatidylglycerol (POPG). These rations mim-
icked the outer mitochondrial membrane. After removing 
chloroform and desiccating, the dried lipid film was resus-
pended in 50 mM HEPES, pH 7, supplemented with 110 mM 
NaCl and 80 mM calcein and extruded with Avanti's mini 
extruder (Alabaster, Ala.). External calcein was removed by 
gel filtration through a 1.5x50 cm Econo-Colunm (Bio-Rad) 
freshly packed with Sephadex 50 (GE Healthcare). CT20 Bax 
peptides were added at concentrations equivalent to those 
used with cells in culture. Calcein fluorescence was excited at 
495 nm and emission spectra recorded between 510 and 550 
nm (excitation/emission slits: 10/3 nm). Samples were main-
tained at 37° C. and a final measurement taken at 24 hours. 
Maximum calcein release was obtained by the addition of 
Triton x 100 (0.1% final concentration) to calcein loaded 
LUVs without nanoparticles that had had been incubated at 
37° C. for 24 hours after the addition of 10 µL DMSO. 
1. In Vivo Experiments 
One to two million MBA-MD-231 cells were harvested 
from culture and injected subcutaneously into the right and 
left flanks of 16 female nude mice (nu/nu, Charles River). 
After 2-3 weeks, tumor volume and growth was assessed by 
ultrasound (VisualSonics Vevo 2100). Mice with tumors were 
injected intratumorally with PBS, unloaded polymeric nano-
particles, or CT20 Bax peptide-loaded polymeric nanopar-
ticles at 4x the concentrations described above. Injections 
were performed twice over a 4-5 day period. Mice were 
observed 0-5 days post-treatments and tumor volume 
assessed by ultrasound. 
2. C-Terminal a9 Helix of Bax Enables Membrane Bind-
ing and Permeabilization 
To develop a novel anti-cancer agent that could be used to 
sensitize cancer cells to treatment, the death-inducing activity 
of Bax was examined. The protein's C-terminal domain was 
a point of focus because of its putative membrane-binding 
properties (Ausili et al., 2008; Martinez-Senac et al., 2001; 
Nechushtan et al., 1999; Schinzel et al., 2004). Mutagenesis 
of the C-terminus of full-length Bax was performed (Table 2). 
As the constitutive expression of N-terminal-tagged Bax 
induced spontaneous cell death. To avoid this, full-length 
HA-tagged Bax was expressed in stably transfected Flp-In 
T-REx 293 cells. Bax constructs were integrated into the 
genome at a single FRT (recombination) site and the levels of 
Bax expression in these isogenic cell lines did not cause 
apoptosis. These experiments determined the role of the 
C-terminus and amino acids Kl 89/Kl 90 in the localization of 
Bax under normal cellular conditions. 
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TABLE2 
Effect of Kl 89/Kl 90 Mutations on Bax Intracellular Localization. 
36 
lysines (K189/Kl90 in the full-length protein) were 
exchanged with leucine (LL) or aspartic acid (EE), did not 
cause calcein release. This indicated that the original lysines 
at positions 189 and 190 were required for optimal membrane Residues 
Bax C-terminus (189-190-191-192) SEQ ID NO 
Wild Type KKMG 54 
(+)to hydrophobic LKMG 55 
KLMG 56 
LLMG 57 
Cellular 
Localization 
Cyto >Mita 
Mi to 
5 permeabilization. CT20 Bax or mutant CT20-LL peptides 
stabilized the lipid membranes and impaired the maximal 
release of calcein upon treatment with detergent (FIG. lC). 
However, this did not occur with the CT20-EE peptide, indi-
cating that the amino acid sequence of the peptide dictated the 
(+)to(-) charge EKMG 
reversal KEMK 
EEMG 
(+)to polar QQMG 
(+)to(-) charge DDMG 
58 
59 
60 
61 
62 
Cytosol 
Cyto ~Mita 
Cytosol 
10 nature of the interaction with lipid membranes. These data 
demonstrated that the CT20 peptide bound to lipid mem-
branes and caused the release of vesicular contents, and fur-
ther demonstrated that the CT20p peptide added rigidity or 
reversal 
Increase ( +) charge, RRMG 
length 
Rearrangement of KMGK 
(++) 
Deletion of ( +) -KMG 
Deletion of ( +) and -MGK 
63 Mi to 
64 Cyto ~Mita 
Cyto ~Mita 
Cytosol 
15 
structure to the lipid membranes. 
3. Expression of the CT20p Peptide Induces Cell Death 
Having established the importance of the C-terminal 
domain of Bax in the intracellular localization of the protein 
and demonstrated the membrane-binding and permeabiliza-
tion properties of the CT20 Bax peptide, the capacity of the 
rearrangement 
Localization of full-length, wild-type (WT) Bax (Bax-KK) 
was distributed among cytosolic and mitochondrial lysates 
(FIG. lA). Specifically, mitochondrial translocation of HA-
tagged wild type Bax (Bax-KK) and Kl89/Kl90 mutants, 
expressed in 293 cells using the Flp-In T-Rex system, was 
examined by immunoblot. p38 MAPK and prohibitin were 
blotted for cytosolic and mitochondrial content, respectively. 
Data are representative of five independent assays. Images 
from full-length blots were cropped for concise presentation. 
N-terminal-deleted Bax (Bax-ANT) was localized primarily 
to mitochondria while the C-terminal-deleted Bax (Bax-
ACT) was retained in the cytosol. These data indicate the role 
20 CT20p peptide to induce cell death was next evaluated. Spe-
cifically, whether the CT20p peptide had cytotoxic properties 
based on its capacity to associate with lipid membranes of 
organelles like mitochondria was assessed. The CT20p pep-
tide domain was fused to a short destabilization domain (DD) 
25 for detection and inducible expression. The CT20p peptide 
fused to DD (DD-CT20) was inducibly expressed in HCT-
116 cells and peptide localization and induction of cell death 
was examined. For a control, the action of the DD-CT20 (KK 
and EE, LL and RR mutants) peptides to DD-tagged full-
30 length (FL) Bax was compared. Induced expression ofDD-
FL Bax did not cause cell death in the absence of apoptotic 
stimuli. 
Gene expression was induced for four hours after previous 
transfection of cells with DD-FL Bax or DD-CT20 peptide of the N- and C-terminal domains in Bax localization (FIG. 
lA). 35 constructs. Constitutive GFP expression on the bi-cistronic 
plasmid was controlled by an IRES element and used to detect 
transfected cells. The mitochondrial translocation of DD-
tagged Bax full-length (FL-Bax) and DD-tagged CT20 pep-
Substitution of Kl 89/Kl 90 with negatively charged resi-
dues, aspartic acid (D) or glutamic acid (E), resulted in the 
cytosolic retention of Bax (Bax-DD, Bax-EE) (FIG. lB). 
Substitution of Kl 89/Kl 90 with positively charged arginine 
(R) (Bax-RR) led to mitochondrial localization (FIG. lB). 40 
Substitution of Kl 89/Kl 90 with a polar amino acid, 
glutamine (Q) (Bax-QQ), led to less mitochondrial Bax, 
when compared Bax-KK and Bax-RR (FIGS. lA and lB). 
Substitution of Kl 89/Kl90 with the hydrophobic amino acid 
leucine (L) (Bax-LL) resulted in mitochondrial association 45 
(FIG. lA). Mutation of Kl89 (Bax-EK) also rendered Bax 
cytosolic, which was not observed by mutation of Kl 90 (Bax-
KMGK) (FIGS. lA and lB, Table 2). These results demon-
strated that the C-terminus of Bax, and Kl 89/Kl 90, modu-
lated the association of the full-length protein with 50 
mitochondria. 
Analysis of the effects of mutations of Kl 89/Kl 90 in full-
length Bax indicated that the C-terminal domain was a pre-
ferred region from which to fashion a membrane-binding and 
possibly a membrane-permeabilizing peptide. Using a com- 55 
mercially synthesized peptide composed of the last twenty 
amino acids (172-192) of the C-terminus of Bax (CT20), the 
ability of CT20p peptide to insert and permeabilize lipid 
membranes was examined. Liposomes contained phospho-
lipids that composed the mitochondrial outer membrane and 60 
were loaded with calcein. FIG. lC demonstrates that the 
CT20p peptide inserted itself into mitochondrial-like lipid 
vesicles and caused the release of calcein. In FIG. lC, the red 
lines indicate maximal release of calcein with Triton X-100. 
The blue lines indicate treatment with DMSO and the green 65 
lines (except for control) indicate treatment with CT20 Bax 
peptides. A mutant CT20 Bax peptide, in which the terminal 
tides, wild-type and EE, LL and RR mutants, was examined in 
Bax+!+ HCT-116 cells by immunoblot.As shown in FIG. 2A, 
most of the DD-tagged FL Bax was found in cytosolic 
extracts. A fraction of DD-FL-Bax was also found in mito-
chondria extracts. The small 15-16 kDbandofDD-CT20KK 
peptides or DD-CT20 mutant peptides (EE, LL, and RR 
(fainter band)) was detected in mitochondrial extracts, indi-
cating that the DD-CT20 peptides were targeting mitochon-
dria. 
Expression of DD-CT20 Bax also caused the mitochon-
drial translocation of a small amount endogenous Bax (FIG. 
2A). Data are representative of two independent assays. In 
FIG. 2A, endogenous Bax was probed with anti-Bax anti-
body. p38 MAPK and prohibitin indicated cytosolic and 
mitochondrial content, respectively. DD-fusions were 
detected with an anti-DD antibody. Controls were cells trans-
fected with empty vector or untransfected. Images from full-
length blots were cropped for concise presentation. 
These results were confirmed by immunofluorescence 
(FIG. 7). In FIG. 7A, cells were fixed and double-stained with 
primary antibodies for HSP60 and DD. The fixed cells were 
then incubated with secondary anti-rabbit-Cy3 and anti-
mouse-Texas red. The overlay appears as white. In FIG. 7B, 
the bar graphs indicate the quantitative assay of co-localiza-
tion of DD-tagged peptides to mitochondria. The measure-
ments are represented by three samples. 
Experiments attaching the CT20 peptides to EGFP con-
firmed the findings that fusion of the CT20p peptide could 
confer membrane binding properties (FIGS. SA and SB). In 
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FIGS. SA and SB, the mitochondrial translocation ofEGFP-
tagged with Bax CT (EGFP-KK) and K189/K190 mutants 
was examined in Bax+/+ HCT-116 cells (A) and Bax-1- HCT-
116 cells (B) by immunoblot. p38 MAPK and Prohibitin were 
assessed for cytosolic and mitochondrial content, respec- 5 
tively. Control sample are untransfected cells. Data are rep-
resentative of five independent assays. Images from full-
length blots were cropped for concise presentation. 
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In FIG. 9, a calcein release assay was performed with 
calcein loaded lipid vesicles prepared with the composition of 
the mitochondrial membrane. Calcein release was measured 
as fluorescence. Controls were calcein release achieved with 
CT20p peptide alone and maximum calcein release obtained 
upon addition of Triton xlOO. A representative experiment of 
two independent experiments is shown. This confirmed that 
cargo is released from nanoparticles only by intracellular 
esterases or acidic pH (Santra et al., 2010). 
The uptake ofDiI-loaded nanoparticles and effect upon the 
viability of HCT-116 cells was evaluated. HCT-116 cells 
were treated with nanoparticles loaded with DiI or DiI +CT20 
peptide (0.07 nM) for24 hours. FIG. 3B shows thatHCT-116 
cells took up nanoparticles, more so for the Bax-deficient 
In FIGS. SC and SD, Bax+i+ HCT-116 cells and Bax_;_ 
HCT-116 cells, respectively, were transfected with the EGFP- 10 
KK or K189/K190 mutants. Time-lapse movies were 
acquired with a 63x Oil objective. For each sample, three 
different fields of view were acquired. Images shown are 
snapshots taken at specified time points. 
The toxicity of DD-CT20 KK peptide was shown when 
expression was induced inHCT-116 cells (FIG. 2B for Bax+/+ 
cells and FIG. 2C for Bax-1- cells). For each sample, three 
different fields of view were acquired. Images are represen-
tative "snapshots" of four independent experiments. Within 20 
five hours of gene induction, the DD-CT20 KK peptide 
caused membrane perturbations and the death of Bax-con-
taining cells. Similar results were observed with the other 
forms ofDD-CT20 (EE, LL and RR) peptides, although the 
death kinetics varied depending on the mutation (LL and RR 25 
mutants took longer to cause death) (FIG. 2B, 5 hours; insets 
15 cells that were highly glycolytic (Boohaker et al., 2011 ). 
in FIG. 2B were increased 3-fold). Moreover, Bax deficiency 
did not impair the lethality of the CT20 Bax peptide. This was 
observed by expressing DD-CT20 KK in Bax_;_ HCT 116 
cells, which caused cell death detectable by 3-5 hours (FIG. 30 
2C, 12 hours). DD-CT20 EE caused membrane disturbances 
by 1 hour of induction and death by 3 hours. This was fol-
lowed by DD-CT20 RR, with loss of membrane integrity 
observed within 3 hours, and DD-CT20 LL causing mem-
brane fluctuations by 5 hours and death by 11 or 12 hours 35 
(FIG. 2C). While mutation of the C-terminal lysines did not 
block mitochondrial translocation (FIG. 2A) or prevent cell 
death, it did alter the timeframe in which death occurred. 
These finding were confirmed with multiple similar experi-
ments, which accounted for differences in transfection effi- 40 
ciency and expression of individual constructs. The data indi-
cate that the C-terminal lysines were needed to "fine tune" the 
interaction of the CT20 peptide with mitochondrial mem-
branes, altering its capacity to induce cell death. (See FIG. lC 
showing that CT20 peptides (WT and mutants) associated 45 
with lipid membranes, which affected membrane rigidity, but 
that only the CT20 WT (containing Kl 89/Kl 90) enabled the 
maximal release of calcein from loaded vesicles). 
While treatment of HCT-116 cells with nanoparticles (un-
loaded) did not cause significant cell death (FIG. 3B), treat-
ment of HCT-116 cells with CT20 peptide-loaded nanopar-
ticles at a concentration of700 pM (or 0.07 nM), caused rapid 
cell death (FIG. 3B). For each sample, three different fields of 
view were acquired. Images are representative "snapshots" of 
two independent experiments. 
To demonstrate that nanoparticles alone (i.e., without the 
CT20 peptide) did not cause death, a DNA-binding dye (Sy-
tox) was utilized to detect membrane rupture of dead cells. 
FIG. 3C shows that minimal (Bax+/+ HCT-116) to no (Bax-1-
HCT-116) cell death was detected upon addition of DiI-
loaded nanoparticles ( 5 µg, 10 µg or 15 µg) as compared to the 
positive control (dead cells). To minimize off-target effects, 
all subsequent experiments were performed at the lowest dose 
of the CT20 peptide (350 pM)-nanoparticles (2.5 µg). 
To visualize the effect of CT20 Bax peptide-nanoparticles 
upon mitochondria, Bax-containing or Bax-deficient HCT-
116 cells were stained with Mitotracker and imaged live cells. 
Bax+!+ (FIG. 4A) and Bax-1- (FIG. 4B) HCT-116 cells were 
treated with AM- or COOH-nanoparticles loaded with CT20 
peptide (350 pM) for 24 hours. To visualize mitochondria, 
cells were treated with MitoTracker Red 580 and time-lapse 
movies were acquired using a 63x Oil objective. FIGS. 4A 
and 4B show "snapshots" at 0, 12, and 24 hour time points. 
These snapshots revealed changes in cell morphology, which 
changes included disruption of mitochondria (reduced or 
faint Mitotracker staining), as well as cell shrinkage and 
membrane perturbations, which were indicative of cell death. 
Similarly, HCT-116 cells were treated with nanoparticles 
loaded with CT20 peptide (350 pM). Cell death was mea-
sured and the loss of membrane integrity was detected within 
three hours of treatment with CT20 Bax peptide-nanopar-
ticles (FIG. 4C). Both AM-nanoparticles and COOH-nano-4. Delivery of the CT20 Peptide Using Polymeric Nano-
particles Kills Cancer Cells 
To determine whether the CT20p peptide could directly kill 
cancer cells, the CT20 wild type peptide was encapsulated in 
polymeric nanoparticles. As the CT20p peptide is amphip-
athic, it can be encapsulated within the hydrophobic pockets 
50 particles containing CT20p peptide were efficacious in initi-
ating cell death (FIG. 4C), although the COOH-nanoparticle 
formulation appeared more effective. These results coupled 
with those in FIG. 2 indicated that the death-inducing activity 
of aliphatic polymeric nanoparticles. FIG. 3A shows a sche- 55 
matic representation of the three dimensional structure of 
aliphatic hyperbranched nanoparticles, in which DiI (fluores-
cent dye) and commercially synthesized CT20 Bax peptides 
were encapsulated into positively charged, aminated (AM) or 
negatively charged, carboxylated (COOH) nanoparticles 60 
(Santra et al., 2010). To verify that the nanoparticles would 
not release the CT20 peptide at neutral pH, calcein loaded 
liposomes were prepared. While the CT20p peptide alone 
(350 pM) did induce the release of calcein (as shown in FIG. 
lC), nanoparticles loaded with CT20 peptide (350 pM) did 65 
not induce the release of calcein from liposomes, indicating 
that the nanoparticles were intact at pH 7 (FIG. 9). 
of the CT20p peptide was independent of endogenous Bax. 
With respect to FIGS. 4A-C, three different fields of view 
were acquired for each sample. Images are representative 
"snapshots" of three independent experiments. 
Whether the CT20 peptide was able to kill the breast cancer 
cells, MCF-7 and MDA-MB-231, was examined. As shown 
in FIG. SA, morphological changes such as cell shrinkage and 
membrane perturbations in MCF-7 cells following treatment 
for 24 hours with AM- or COOH-nanoparticles containing 
the CT20p peptide (350 pM) were observed. For each sample, 
three different fields of view were acquired. Images are rep-
resentative "snapshots" of three independent experiments 
Most MCF-7 cells died within 24 hours, while loss of mem-
brane integrity was detected by 3 hours of treatment (FIG. 
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SB). In FIG. SC, the live cell imaging experiment revealed 
vacuolization, membrane fluctuations, and cell shrinkage of 
MDA-MB-231 cells following treatment with CT20 peptide-
nanoparticles. Within three hours, increased membrane rup-
turewas detected in MDA-MB-231 cellstreatedwithCOOH- 5 
nanoparticles loaded with CT20 peptide (FIG. SD). These 
results demonstrated that the CT20 peptide, once introduced 
into cells, rapidly triggered cell death. While the CT20 pep-
tide encapsulated in nanoparticles caused the death of four 
cancer cell lines (colon and breast), the CT20 Bax peptide/ 10 
nanoparticle formulation was less effective inducing death in 
two lung cancer cell lines. This data indicated that that dif-
ferences in the uptake and efficacy of the CT20 peptide/ 
nanoparticles could exist that are related to the physiology of 
the cancer cell. 15 
5. The Death-Inducing Activity of the CT20p Peptide is 
Independent ofCaspases and Resistant to Bcl-2. 
To investigate the mechanism by which the CT20p peptide 
was inducing cell death, MDA-MB-231 cells were treated 
with CT20 Bax peptide/nanoparticles (350 pM). A caspase 20 
inhibitor (e.g., ZVAD-Fmk and/or CDDP) was added or 
Bcl-2 was overexpressed. As shown in FIG. 6A, the CT20 
peptide caused significant loss of membrane integrity, which 
was largely unaffected by caspase inhibition with Z-VAD-
FMK. In contrast, treatment of MDA-MB-231 cells with 25 
cisplatin (CDDP) induced cell death that was inhibited by 
ZVAD-FMK. These results indicated that the death pathway 
induced by the CT20p peptide was different than CDDP and 
was independent of the effector caspases inhibited by ZVAD-
FMK. When Bcl-2 was overexpressed, the overexpression 30 
did not impair the death activity of the CT20 Bax peptide, but 
rather slightly enhanced it. Bcl-2 overexpression impaired 
death induced by CDDP (FIG. 6A). Administration of CD DP 
followed by treatment with the CT20 peptide was the most 
effective in inducing cell death, which was not inhibited by 35 
ZVAD-FMK or Bcl-2 (FIG. 6A). The expression ofBcl-2 by 
transfected cells was confirmed by immunoblotting lysates 
prepared from cells (FIG. 10). 
In FIG. 10, cells were transiently transfected with Bcl-2, 
treated with nanoparticles/CT20. Lysates were immunoblot- 40 
ted for Bcl-2. Controls are untransfected cells (UT) and 
untreated cells (control). * denotes a non-specific band. A 
representative blot of two performed is shown. 
While Sytox is good indicator of cell death, it does not 
distinguish between apoptotic and necrotic cell death. There- 45 
fore, to determine whether the CT20p peptide induced apop-
totic cell death, the amount of membrane asymmetry caused 
by flipping of phospholipids in the plasma membrane using a 
violet ratiometric probe was determined. In FIG. 6B, dot blots 
show the comparison of loss of membrane integrity to 50 
changes in membrane symmetry in MDA-MB-231 cells 
treated with CT20p peptide and/or CDDP. Treatment with the 
CT20p peptide encapsulated in nanoparticles enabled pen-
etration of the DNA-binding dye (as shown in FIG. 6A), but 
did not promote changes in membrane symmetry. This was 55 
minimally affected by caspase inhibition or Bcl-2 expression. 
In contrast, contrast, CDDP induced significant alterations in 
the membrane symmetry detectable by the violet ratiometric 
probe, which alterations were inhibited by ZVAD-FMK or 
Bcl-2 (FIG. 6B; data shown is representative of more than 60 
three independent experiments). The combination treatment 
of CDDP and CT20p peptide was the most efficacious and 
was minimally affected by caspase inhibition or Bcl-2 expres-
sion (FIG. 6B). These findings indicate that the CT20 peptide 
engages in a death mechanism distinct from that of CDDP, 65 
and that this distinct mechanism is independent of ZVD-
FMK inhibited-caspases and is resistant to Bcl-2. 
40 
To demonstrate that the CT20 peptide could kill cancer 
cells in vivo, a small scale murine tumor experiment was 
performed. MDA-MB-231 cells were implanted in the flanks 
of nude mice. Initial growth of tumors was detected after 2 
weeks. At this time tumors were measured, and over a 4-5 day 
period, the mice were treated with intratumoral injections of 
PBS, unloaded or empty nanoparticles (NP), or CT20 pep-
tide/nanoparticles. The CT20 peptide prevented tumor 
growth as compared to empty nanoparticles or a PBS-treated 
tumor. (FIG. 6C; results displayed in the graph show the 
change in tumor volume during the four days of treatment and 
are a representative of three independent experiments). These 
results demonstrated that the CT20 peptide was effective not 
only in tissue culture, but also in the tumor environment. 
Moreover, the ultrasound data in FIG. 6D showed little to 
no observable damage of normal tissue surrounding the 
regressing tumors treated with the CT20 peptide. FIG. 6D 
provides representative ultrasound image of changes in tumor 
volume induced by treatment on days 0, 2 and 4 with the 
unloaded or CT20 peptide loaded nanoparticles. These find-
ings indicate reduced uptake or effectiveness in non-cancer-
ous cells. 
Collectively, these data demonstrated that the C-terminal 
domain of Bax has membrane-binding capacity. The CT20p 
peptide permeabilized membranes and caused cell death. The 
CT20 peptide, unlike the full-length Bax protein, caused a 
lethal cascade that resulted in membrane rupture that is not 
characteristic of conventional apoptosis. The amphipathic 
features of the CT20 peptide made it amenable to encapsula-
tion in nanoparticles and delivery to cancer cells. The CT20 
peptide caused the death of colon and breast cancer cells, even 
in the absence of endogenous Bax or expression ofBcl-2, and 
led to reduced tumor volume in a murine model. The CT20 
peptide caused cell death in a manner that was different from 
the apoptotic mechanism activated by CDDP. 
Central to the lethal function of Bax is the membrane 
binding capacity of domains like the C-terminal alpha-9 
helix. Loss of the C-terminus, or mutagenesis of Kl 89/Kl 90, 
modulated the ability of Bax to associate with mitochondria. 
The CT20 peptide, derived from the C-terminal a9 helix of 
Bax, penetrated and permeabilized lipid vesicles. The CT20 
Bax peptide, when encapsulated innanoparticles, was toxic at 
picomolar concentrations. The CT20 Bax peptide/nanopar-
ticle mixture induced morphological features of cell death 
such loss of membrane integrity and cell shrinkage, but did 
not cause the changes in membrane symmetry that character-
izes apoptosis. Use of the Bax CT20 peptide/nanoparticles as 
an anti-cancer agent was demonstrated when breast cancer 
cell lines succumbed to treatment as indicated by increased 
loss of membrane integrity that was not impaired by caspase 
inhibition or Bcl-2 expression. The CT20 peptide caused a 
form of cell death that was mechanistically different from 
typical anti-cancer drugs like CDDP. 
The data indicate that the CT20p peptide kills cells caused 
the formation of pores in mitochondrial membranes. The 
CT20p peptide was efficient at forming pores in zwitterionic 
and anionic lipid membranes, leading to the release of calcein 
from loaded lipid vesicles. FIG. 11, for example, shows a 
model for a membrane pore formed by the CT20 Bax peptide. 
Control peptides did not permeabilize lipid membranes, caus-
ing calcein release, which indicated that the observed pore 
formation was specific to the CT20 Bax peptide. Second-
order rate kinetics revealed that initial pore formation by the 
CT20p peptide was slow, which was followed by a faster rate 
of assembly. The data indicate that the CT20p peptide formed 
pores leading to membrane destabilization, ion exchange, 
and/or the release of sequestered molecules. 
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Pore-forming proteins or peptides that can spontaneously 
insert into lipid membranes and form stable pores have sig-
nificant biological interest and clinical application. As dem-
onstrated herein, the CT20 peptide, a shorter version of the a9 
helix of Bax (amino acids 172-192), caused cell death indi-
cated by membrane rupture. These findings indicate that the 
CT20 peptide may cause necrotic-like cell death, rather than 
conventional apoptosis, and therefore has the potential for 
additive effects in combinatorial therapies with agents like 
CDDP that induce apoptosis. The data presented herein show 10 
that a small amount of the CT20 peptide was lethal under 
conditions when the apoptotic machinery is intact (such as 
Bax-containing HCT-116 cells) or when the apoptosis 
machinery is defective (such as Bax deficient HCT-116 cells). 
The CT20 peptide was also effective under conditions of 15 
effector caspase inhibition or Bcl-2 over expression. These 
data indicate that the CT20 peptide may be a potent killing 
tool in cancers with abnormal levels of anti-apoptotic pro-
teins, as well as cancers in which other survival signaling 
mechanism may be irregular. FIG. 12, for example, shows a 20 
hypothetical cell death pathway for CT20p peptide using a 
basic model of apoptotic and non-apoptotic cell death. 
Example 6 
25 
Pore Formation by CT20p Peptide 
42 
normal, by 30-60 degrees. The tryptophan residue embed into 
zwitterionic membranes at 8-9 A from membrane center. 
Membrane anionic charge causes a deeper insertion oftryp-
tophan for BaxC-KK and BaxC-LL but not BaxC-EE. Com-
bined with pore stoichiometry, these data suggest a pore 
model where eight peptide molecules form an "a/~-ring" 
structure with pore inner diameter of 20-22 A. These results 
identified a strong membranotropic activity of Bax C-termi-
nus and proposed a new mechanism by which peptides can 
efficiently perforate cell membranes and thus be used as cyto-
toxic agents. 
Additionally, membrane insertion of the peptide and sub-
sequent pore formation was mediated mainly by hydrophobic 
rather than electrostatic interactions. In the presence of bulk 
water, the peptides assume an a/~-type structure, with the 
~-strands and a-helices significantly tilted relative to the 
membrane normal. Altogether, the data are consistent with an 
octameric "a/~-ring" structure with an internal pore diameter 
ofat least 13 A to 20-22 A that caneffectivelytransfercalcein 
and larger molecules. The data establish a foundation for 
characterization of the molecular structure of the a/~ ring 
transmembrane pore formed by Bax-derived peptides. 
Example of Killing Microbial Cells 
FIG. 13 shows a comparison ofCT20p peptide with anti-
microbial peptides and apoptosis-inducing peptides. 
Attributes are shared among the peptides. FIG. 14 shows that 
Ct20p peptide inhibited the growth of E. coli, a gam negative 
bacteria, in a dose dependent manner, inhibiting 50% of the 
An analysis of formation of relatively large membrane 
pores by Bax C-terminal 20-reside peptide (CT20p) and two 
mutants where the two native lysines are replaced either with 
glutamates (charge reversal mutation) or leucines (charge 
neutralization mutation) were examined. The three peptides 
demonstrate distinct potencies to form pores in both zwitte-
rionic and anionic membranes that transport calcein 
(Mr-623). The most efficient pores are formed by the wild-
type peptide in anionic membranes. The kinetics of calcein 
release at various concentrations of the three peptides allowed 
identification of the second-order rate constants of pore for-
mation within the membrane, the affinity constants of peptide 
units composing the pore, and the oligomeric pore structure. 
Nucleation of the pore is shown to be relatively slow and 
involve 2-3 peptide molecules, followed by a faster process of 
assembly of the pore that includes up to eight peptide mol-
ecules. Structural studies led to a model of an octameric 
transmembrane pore with an inner diameter of 20-22 A. 
Analysis of the kinetics of calcein release from lipid vesicles 
allows determination of rate constants of pore formation, 
peptide-peptide affinities within the membrane, the oligo-
meric state oftransmembrane pores, and the role of the lysine 
residues. 
30 growth of bacteria at a dose of 50 µg. The inhibition of growth 
began around 3 hours and reached a plateau at 13 hours, see 
graph. These results compared to control peptide XL or no 
peptide, in which growth began at 3 hours and plateaued at 
35 6-7 hours. TheE. coli were grown in the presence ofa peptide, 
concentrations ofCT20p peptide or for control, SCR peptide, 
or no peptide for a control, in standard conditions for growing 
bacteria in broth media. 
FIG. 15 shows counts of the bacterial colonies from the 
40 broth culture of FIG. 14. The bacterial culture media was 
plated after 24 hours of treatment/exposure to Ct20p or the 
control conditions, a peptide (SCR) or no peptide and addi-
tion of DMSO, and the resulting colonies were counted. 
There were few bacterial colonies detected with CT20p treat-
45 ment of 24 hours, which indicated that the effects of CT20p 
peptide were bactericidal, not bacteriostatic (inhibition of 
growth). A conclusion was that the inhibition of growth seen 
in FIG. 14 was due to the killing or lysing of bacteria. 
All of the compositions and/or methods disclosed and 
50 claimed herein can be made and executed without undue 
In summary, the C-terminal 20-residue stretch of Bax has 
the capability of forming relatively large membrane pores 
with a radius of at least 13 A. Replacement of the two lysine 
residues close to the C-terminus with anionic glutamate or 
nonpolar leucine residues reduce the pore forming activity of 55 
the peptide, but the mutant peptides are still quite capable 
pore formers. In general, the pore formation is a two-stage 
process, nucleation and assembly of the final pore structure 
that includes up to eight peptide molecules, and is stabilized 
by intermolecular interaction energies of -10 to -13 kcal/ 60 
mo!, which is quite significant for 20-mer peptides. 
Additionally, the pore structure was analyzed by polarized 
Fourier transform infrared, circular dichroism, and fluores-
cence experiments on the peptides reconstituted in phospho-
lipid membranes. The peptides assumed an a/~-type second- 65 
ary structure within membranes. Both ~-strands and 
a-helices are significantly tilted relative to the membrane 
experimentation in light of the present disclosure. It will be 
apparent to those skilled in the art that various modifications 
and variations can be made in the present invention without 
departing from the scope or spirit of the invention. 
More specifically, certain agents which are both chemi-
cally and physiologically related can be substituted for the 
agents described herein while the same or similar results can 
be achieved. All such similar substitutes and modifications 
apparent to those skilled in the art are deemed to be within the 
spirit, scope and concept of the invention as defined by the 
appended claims. 
Other embodiments of the invention will be apparent to 
those skilled in the art from consideration of the specification 
and practice of the invention disclosed herein. It is intended 
that the specification and examples be considered as exem-
plary only, with a true scope and spirit of the invention being 
indicated by the following claims. 
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TABLE 1 
SE UENCES 
Description Sequence 
CT20Bax WT VTIFVAGVLTASLTIWKKMG 
CT20Bax EE VTIFVAGVLTASLTIWEEMG 
CT20Bax LL VTIFVAGVLTASLTIWLLMG 
CT20Bax RR VTIFVAGVLTASLTIWRRMG 
BAX-KK (for) 5'-GGATCACTCTCGGCCTGGACACCATGGG 
GATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
BAX-KK (rev) 5'-CGTCGACTGCAGAATTCTCAGCCCATC 
TTCTTCCAGATGGTGAGCGAGG-3' 
BAX-LlliT (1-19) 5'-CCGGGGAGCAGCCCCATATGTACCCAT 
(for) ACGATGTTCCAGATTACGCTATGAAG 
ACAGGGGCCCTTTTGC-3' 
BAX-LlliT (1-19) 5'-CGTCGACTGCAGAATTCTCAGCCCATCTT 
(rev) CTTCCAGATGGTGAGCGAGG-3' 
US 9,040,662 B2 
45 46 
TABLE 1-continued 
SE UENCES 
Seq ID No. Description Sequence 
9 BAX-LI.CT (1 73- 5'-GGATCACTCTCGGCCTGGACACCATGG 
192) (for) GGATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
10 BAX-LI.CT (1 73- 5'-CGTCGACTGCAGAATTCTCAGGTCTGCCA 
192) (rev) CGTGGGCGTCCAAAG-3' 
11 BAX-LL (for) 5'-GGATCACTCTCGGCCTGGACACCATGG 
GGATGTACC CATACGA TGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
12 BAX-LL (rev) 5'-CGTCGACTGCAGAATTCTCAGCCCATGA 
GGAGCCAGATGGTGAGCGAGG-3' 
13 BAX-DD (for) 5'-GGATCACTCTCGGCCTGGACACCATG 
GGGATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
14 BAX-DD (rev) 5'-CGTCGACTGCAGAATTCTC 
AGCCCATGTCGTCCCAGATGGTGAGCGAGG-3' 
15 BAX-EE (for) 5'-GGATCACTCTCGGCCTGGACACCATGGG 
GATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
16 BAX-EE (rev) 5'-CGTCGACTGCAGAATTCTCAGCCC 
ATCTCCTCCCAGATGGTGAGCGAGG-3' 
17 BAX-RR (for) 5'-GGATCACTCTCGGCCTGGACACCATG 
GGGATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
18 BAX-RR (rev) 5'-CGTCGATCTCAGCCCATTCGTCGCC 
ACATGGTGAGCGAGG-3' 
19 BAX-QQ (for) 5'-GGATCACTCTCGGCCTGGACACCAT 
GGGGATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
20 BAX-QQ (rev) 5'-CGTCGACTGCAGAATTC TCAGCCCATC 
TGCTGCCAGATGGTGAGCGAGG-3' 
21 BAX-KMGK 5'-GGATCACTCTCGGCCTGGACACCATG 
(for) GGGATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG -3' 
22 BAX-KMGK 5'-CGTCGACTGCAGAATTCTCACTTCCCCA 
(rev) TCTTCCAGATGGTG AGCGAGG-3' 
23 BAX-EK (for) 5'-GGATCACTCTCGGCCTGGACACCATG 
GGGATGTACCCATACGATGTTCCAG 
ATTACGCTGACGGGTCCGGGGAGCAG-3' 
24 BAX-EK (rev) 5'-CGTCGACTGCAGAATTCTCAGCCCA 
TCTTCTCCCAGATGGTGAGCGAGG-3' 
25 GFP-CT-WT (for) 5'-GGATCACTCTCGGCCTGGACGA 
GGATATCATGGTGAGCAAG-3' 
26 GFP-CT-WT (rev) 5'-CGTCGACTGCAGATATCTCAGCCCA 
TCTTCTTC CAGATGGTGAGCGAGG 
CGGTGAGCACTCCCGCCACAAAGATG 
GTCACGGTGTTATCTAGATC-3' 
27 GFP-CT-EE (for) 5'-GGATCACTCTCGGCCTGGACGA 
GGATATCATGGTGAGCAAG-3' 
28 GFP-CT-EE (rev) 5'-CGTCGACTGCAGATATCTCAGCCCATC 
TCCTCC CAGATGGTGAGCGAGGC 
GGTGAGCACTCCCGCCACAAAGATGG 
TCACGGTGTTATCTAGATC-3' 
29 GFP-CT-RR (for) 5'-GGATCACTCTCGGCCTGGACGA 
GGATATCATGGTGAGCAAG-3' 
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TABLE 1-continued 
SE UENCES 
Seq ID No. Description Sequence 
30 GFP-CT-RR (rev) 5'-CGTCGACTGCAGATATCTCAGCCCATG 
AGGAGC CAGATGGTGAGCGAGGCGGTG 
AGCACTCCCGCCACAAAGATGG 
TCACGGTGTTATCTAGATC-3' 
31 DD-CT-WT (for) 5'-AATTCTGTGACCATCTTTGTGGCGGGA 
GTGCTCACCGCCTCGCTCACCATC 
TGGAAGAAGATGGGCTGA-3' 
32 DD-CT-WT (rev) 5'-GATCTCAGCCCATCTTCTTCCAGATGG 
TGAGCGAGGCGGTGAGCACTCCCG 
CCACAAAGATGGTCACAG-3' 
33 DD-CT-EE (for) 5'-AATTCTGTGACCATCTTTGTGGC 
GGGAGTGCTCACCGCCTCGCTCACCA 
TCTGGGAGGAGATGGGCTGA-3' 
34 DD-CT-EE (rev) 5'-GATCTCAGCCCATCTCCTCCCAGA 
TGGTGAGCGAGGCGGTGAGCA 
CTCCCGCCACAAA GATGGTCACAG-3' 
35 DD-CT-LL (for) 5'-AATTCTGTGACCATCTTTGTGGCGGGA 
GTGCTCACCGCCTCGCTCACCATCTGGC 
TCCTCATGGGCTGA-3' 
36 DD-CT-LL (rev) 5'-GATCTCAGCCCATGAGGAGCCAGA 
TGGTGAGCGAGGCGGTGA 
GCACTCCCGCCACAAA GATGGTCACAG-3' 
37 DD-CT-RR (for) 5'-AATTCTGTGACCATCTTTGTGGCGGGA 
GTGCTCACCGCCTCGCTCAC 
CATCTGGCGACGAATGGGCTGA-3' 
38 DD-CT-RR (rev) 5-GATCTCAGCCCATTCGTCGCCAGA 
TGGTGAGCGAGGCGGTGAGCAC 
TCCCGCCACAAA GATGGTCACAG-3' 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 64 
<210> SEQ ID NO 1 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
Val Thr Ile Phe 
1 
Lys Lys Met Gly 
20 
1 
Val 
5 
<210> SEQ ID NO 2 
<211> LENGTH, 20 
<212> TYPE, PRT 
Ala Gly Val Leu 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
Thr Ala Ser Leu Thr Ile 
10 15 
Trp 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 2 
Val Thr Ile Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp 
1 5 10 15 
Glu Glu Met Gly 
20 
48 
<210> SEQ ID NO 3 
<211> LENGTH, 20 
<212> TYPE, PRT 
49 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 9,040,662 B2 
-continued 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 3 
Val Thr Ile Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp 
1 5 10 15 
Leu Leu Met Gly 
20 
<210> SEQ ID NO 4 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 4 
Val Thr Ile Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp 
1 5 10 15 
Arg Arg Met Gly 
20 
<210> SEQ ID NO 5 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 5 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 6 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 
cgtcgactgc agaattctca gcccatcttc ttccagatgg tgagcgagg 
<210> SEQ ID NO 7 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 7 
49 
ccggggagca gccccatatg tacccatacg atgttccaga ttacgctatg aagacagggg 60 
cccttttgc 69 
<210> SEQ ID NO 8 
50 
<211> LENGTH, 49 
<212> TYPE, DNA 
51 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 8 
cgtcgactgc agaattctca gcccatcttc ttccagatgg tgagcgagg 
<210> SEQ ID NO 9 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 9 
49 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 10 
<211> LENGTH, 44 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 10 
cgtcgactgc agaattctca ggtctgccac gtgggcgtcc aaag 
<210> SEQ ID NO 11 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 11 
44 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 12 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 12 
cgtcgactgc agaattctca gcccatgagg agccagatgg tgagcgagg 
<210> SEQ ID NO 13 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 13 
49 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
52 
acgggtccgg ggagcag 
<210> SEQ ID NO 14 
<211> LENGTH, 49 
<212> TYPE, DNA 
53 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 14 
cgtcgactgc agaattctca gcccatgtcg tcccagatgg tgagcgagg 
<210> SEQ ID NO 15 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 15 
77 
49 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 16 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 16 
cgtcgactgc agaattctca gcccatctcc tcccagatgg tgagcgagg 
<210> SEQ ID NO 17 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 17 
49 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 18 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 18 
cgtcgatctc agcccattcg tcgccacatg gtgagcgagg 
<210> SEQ ID NO 19 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
40 
54 
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-continued 
synthetic construct 
<400> SEQUENCE, 19 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 20 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 20 
cgtcgactgc agaattctca gcccatctgc tgccagatgg tgagcgagg 
<210> SEQ ID NO 21 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 21 
49 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 22 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 22 
cgtcgactgc agaattctca cttccccatc ttccagatgg tgagcgagg 
<210> SEQ ID NO 23 
<211> LENGTH, 77 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 23 
49 
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg 60 
acgggtccgg ggagcag 77 
<210> SEQ ID NO 24 
<211> LENGTH, 49 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 24 
cgtcgactgc agaattctca gcccatcttc tcccagatgg tgagcgagg 
<210> SEQ ID NO 25 
49 
56 
<211> LENGTH, 41 
<212> TYPE, DNA 
57 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 25 
ggatcactct cggcctggac gaggatatca tggtgagcaa g 
<210> SEQ ID NO 26 
<211> LENGTH, 95 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 26 
41 
cgtcgactgc agatatctca gcccatcttc ttccagatgg tgagcgaggc ggtgagcact 60 
cccgccacaa agatggtcac ggtgttatct agate 95 
<210> SEQ ID NO 27 
<211> LENGTH, 41 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 27 
ggatcactct cggcctggac gaggatatca tggtgagcaa g 
<210> SEQ ID NO 28 
<211> LENGTH, 95 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 28 
41 
cgtcgactgc agatatctca gcccatctcc tcccagatgg tgagcgaggc ggtgagcact 60 
cccgccacaa agatggtcac ggtgttatct agate 95 
<210> SEQ ID NO 29 
<211> LENGTH, 41 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 29 
ggatcactct cggcctggac gaggatatca tggtgagcaa g 
<210> SEQ ID NO 30 
<211> LENGTH, 95 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 30 
41 
cgtcgactgc agatatctca gcccatgagg agccagatgg tgagcgaggc ggtgagcact 60 
58 
59 
cccgccacaa agatggtcac ggtgttatct agate 
<210> SEQ ID NO 31 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 31 
95 
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctggaagaag 60 
atgggctga 69 
<210> SEQ ID NO 32 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 32 
gatctcagcc catcttcttc cagatggtga gcgaggcggt gagcactccc gccacaaaga 60 
tggtcacag 69 
<210> SEQ ID NO 33 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 33 
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctgggaggag 60 
atgggctga 69 
<210> SEQ ID NO 34 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 34 
gatctcagcc catctcctcc cagatggtga gcgaggcggt gagcactccc gccacaaaga 60 
tggtcacag 69 
<210> SEQ ID NO 35 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 35 
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctggctcctc 60 
atgggctga 69 
60 
<210> SEQ ID NO 36 
<211> LENGTH, 69 
<212> TYPE, DNA 
61 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 36 
gatctcagcc catgaggagc cagatggtga gcgaggcggt gagcactccc gccacaaaga 60 
tggtcacag 69 
<210> SEQ ID NO 37 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 37 
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctggcgacga 60 
atgggctga 69 
<210> SEQ ID NO 38 
<211> LENGTH, 69 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION: Description of artificial sequence note 
synthetic construct 
<400> SEQUENCE, 38 
gatctcagcc cattcgtcgc cagatggtga gcgaggcggt gagcactccc gccacaaaga 60 
tggtcacag 69 
<210> SEQ ID NO 39 
<211> LENGTH, 25 
<212> TYPE, PRT 
<213> ORGANISM, Bos taurus 
<400> SEQUENCE, 39 
Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro 
1 5 10 15 
Ser Ile Thr Cys Val Arg Arg Ala Phe 
20 25 
<210> SEQ ID NO 40 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM, Bos taurus 
<400> SEQUENCE, 40 
Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg 
1 5 10 
<210> SEQ ID NO 41 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Apis mellifera 
<400> SEQUENCE, 41 
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu 
1 5 10 15 
62 
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Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln 
20 25 
<210> SEQ ID NO 42 
<211> LENGTH, 24 
<212> TYPE, PRT 
<213> ORGANISM, Rana acanthi 
<400> SEQUENCE, 42 
Phe Leu Pro Val Leu Ala Gly Ile Ala Ala Lys Val Val Pro Ala Leu 
1 5 10 15 
Phe Cys Lys Ile Thr Lys Lys Cys 
20 
<210> SEQ ID NO 43 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Rana acanthi 
<400> SEQUENCE, 43 
Phe Leu Gly Gly Leu Ile Lys Ile Val Pro Ala Met Ile Cys Ala Val 
1 5 10 15 
Thr Lys Lys Cys 
20 
<210> SEQ ID NO 44 
<211> LENGTH, 37 
<212> TYPE, PRT 
<213> ORGANISM, Trigoniopthalmus alternatus 
<400> SEQUENCE, 44 
Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg 
1 5 10 15 
Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala 
20 25 30 
Thr Gln Ile Ala Lys 
35 
<210> SEQ ID NO 45 
<211> LENGTH, 34 
<212> TYPE, PRT 
<213> ORGANISM, Rana acanthi 
<400> SEQUENCE, 45 
Ala Leu Trp Lys Thr Met Leu Lys Lys Leu Gly Thr Met Ala Leu His 
1 5 10 15 
Ala Gly Lys Ala Ala Leu Gly Ala Ala Ala Asp Thr Ile Ser Gln Gly 
20 25 30 
Thr Gln 
<210> SEQ ID NO 46 
<211> LENGTH, 23 
<212> TYPE, PRT 
<213> ORGANISM, Rana acanthi 
<400> SEQUENCE, 46 
Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe 
1 5 10 15 
Val Gly Glu Ile Met Asn Ser 
20 
<210> SEQ ID NO 47 
<211> LENGTH, 20 
<212> TYPE, PRT 
65 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, synthetic construct; CT20p REV peptide 
<400> SEQUENCE, 47 
Gly Met Lys Lys Trp Ile Thr Leu Ser Ala Thr Leu Val Gly Ala Val 
1 5 10 15 
Phe Thr Ile Val 
20 
<210> SEQ ID NO 48 
<211> LENGTH, 14 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; KLA peptide 
<400> SEQUENCE, 48 
Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys 
1 5 10 
<210> SEQ ID NO 49 
<211> LENGTH, 29 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 49 
Asp Gly Asn Phe Asn Trp Gly Arg Val Val Ala Leu Phe Tyr Phe Ala 
1 5 10 15 
Ser Lys Leu Val Leu Lys Val Pro Glu Leu Ile Arg Thr 
20 25 
<210> SEQ ID NO 50 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 50 
Met Arg Pro Glu Ile Trp Ile Ala Gln Glu Leu Arg Arg Ile Gly Asp 
1 5 10 15 
Glu Phe Asn Ala 
20 
<210> SEQ ID NO 51 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 51 
Glu Asp Ile Ile Arg Asn Ile Ala Arg His Leu Ala Gln Val Gly Asp 
1 5 10 15 
Ser Met Asp Arg 
20 
<210> SEQ ID NO 52 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 52 
66 
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Gly Gln Val Gly Arg Gln Leu Ala Ile Ile Gly Asp Asp Ile Asn Arg 
1 5 10 15 
<210> SEQ ID NO 53 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; CT20p peptide 
<220> FEATURE, 
<221> NAME/KEY, MOD_RES 
<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, ACETYLATION 
<400> SEQUENCE, 53 
Val Ile Thr Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp 
1 5 10 15 
Lys Lys Met Gly 
20 
<210> SEQ ID NO 54 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; Bax intracellular 
localization peptide 
<400> SEQUENCE, 54 
Lys Lys Met Gly 
1 
<210> SEQ ID NO 55 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 55 
Leu Lys Met Gly 
1 
<210> SEQ ID NO 56 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 56 
Lys Leu Met Gly 
1 
<210> SEQ ID NO 57 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 57 
Leu Leu Met Gly 
1 
68 
<210> SEQ ID NO 58 
<211> LENGTH, 4 
<212> TYPE, PRT 
69 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 58 
Glu Lys Met Gly 
1 
<210> SEQ ID NO 59 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 59 
Lys Glu Met Lys 
1 
<210> SEQ ID NO 60 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 60 
Glu Glu Met Gly 
1 
<210> SEQ ID NO 61 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 61 
Gln Gln Met Gly 
1 
<210> SEQ ID NO 62 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 62 
Asp Asp Met Gly 
1 
<210> SEQ ID NO 63 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
70 
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<400> SEQUENCE, 63 
Arg Arg Met Gly 
1 
<210> SEQ ID NO 64 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic construct; mutant Bax intracellular 
localization peptide 
<400> SEQUENCE, 64 
Lys Met Gly Lys 
1 
What is claimed is: 
1. A method of permeabilizing membranes of cells, com-
prising, administering to the cell an effective amount of a) a 
C-terminal B cell lymphoma-2 (Bcl-2)-associated X protein 
(Bax) peptide (CT20p peptide), wherein the CT20p peptide 
comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, 
or a combination of two or more of SEQ ID NOs: 1-4, orb) a 
composition comprising a CT20p peptide, wherein the com-
position comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID 
NO: 4, or a combination of two or more of SEQ ID NOs: 1-4. 
2. The method of claim 1, further comprising repeating the 
administration of the CT20p peptide or the composition com-
prising the CT20p peptide. 
3. The method of claim 1, comprising administering the 
CT20p peptide or CT20p peptide composition directly into a 
tumor cell. 
4. The method of claim 1, further comprising inducing cell 
death. 
5. The method of claim 4, wherein the cell death occurs 
independently of endogenous Bax activity, or endogenous 
caspase activity, or both. 
6. The method of claim 4, wherein the cell death is resistant 
to B cell lymphoma-2 (Bcl-2) over-expression. 
7. The method of claim 1, wherein the CT20p peptide is 
encapsulated in polymeric nanoparticles. 
20 8. The method of claim 7, wherein the nanoparticles are 
aminated. 
9. The method of claim 7, wherein the nanoparticles are 
carboxylated. 
10. The method of claim 1, further comprising administer-
25 ing to the cell one or more therapeutic agents. 
11. The method of claim 1, wherein the cell is a cancer cell. 
12. The method of claim 11, wherein the cancer cell is a 
breast cancer cell, colorectal cancer cell, or lung cancer cell, 
or wherein the cancer cell is a drug resistant cancer cell. 
30 13. The method of claim 1, wherein the membrane is a 
mitochondrial membrane. 
14. A composition for permeabilizing membranes in cells, 
comprising, a CT20p peptide, wherein the CT20p peptide 
comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, 
35 or a combination of two or more of SEQ ID NOs: 1-4. 
15. The composition of claim 14, wherein the CT20p pep-
tide is encapsulated in polymeric nanoparticles. 
16. The composition of claim 15, wherein the nanopar-
ticles are aminated. 
40 17. The composition of claim 15, wherein the nanopar-
ticles are carboxylated. 
18. The composition of claim 14, further comprising one or 
more therapeutic agents. 
* * * * * 
